WO2024104412A1 - Attenuated interferon proteins and fragments and multifunctional polypeptides and conjugates - Google Patents
Attenuated interferon proteins and fragments and multifunctional polypeptides and conjugates Download PDFInfo
- Publication number
- WO2024104412A1 WO2024104412A1 PCT/CN2023/131937 CN2023131937W WO2024104412A1 WO 2024104412 A1 WO2024104412 A1 WO 2024104412A1 CN 2023131937 W CN2023131937 W CN 2023131937W WO 2024104412 A1 WO2024104412 A1 WO 2024104412A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- alkyl
- group
- seq
- ifnα2b
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 159
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 138
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 135
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 134
- 230000002238 attenuated effect Effects 0.000 title claims description 23
- 102000014150 Interferons Human genes 0.000 title description 14
- 108010050904 Interferons Proteins 0.000 title description 14
- 230000027455 binding Effects 0.000 claims abstract description 100
- 239000000427 antigen Substances 0.000 claims abstract description 41
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 124
- 229940127121 immunoconjugate Drugs 0.000 claims description 122
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 98
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 72
- 230000000694 effects Effects 0.000 claims description 70
- 239000000126 substance Substances 0.000 claims description 69
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 67
- 125000005647 linker group Chemical group 0.000 claims description 66
- 238000006467 substitution reaction Methods 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 48
- 235000001014 amino acid Nutrition 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 102100027207 CD27 antigen Human genes 0.000 claims description 32
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 32
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 27
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 27
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 27
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims description 25
- 235000018417 cysteine Nutrition 0.000 claims description 25
- 230000011664 signaling Effects 0.000 claims description 25
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims description 24
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 23
- -1 mono-substituted butenedioic acid Chemical class 0.000 claims description 23
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 22
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 22
- 102000035195 Peptidases Human genes 0.000 claims description 22
- 108091005804 Peptidases Proteins 0.000 claims description 22
- 239000004365 Protease Substances 0.000 claims description 22
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 21
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims description 21
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims description 20
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 19
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 19
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 19
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 19
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 15
- 102000006992 Interferon-alpha Human genes 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000002227 Interferon Type I Human genes 0.000 claims description 14
- 108010014726 Interferon Type I Proteins 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 13
- 108010006035 Metalloproteases Proteins 0.000 claims description 13
- 102000005741 Metalloproteases Human genes 0.000 claims description 13
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 claims description 12
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 12
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 12
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 12
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 12
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 210000004899 c-terminal region Anatomy 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 7
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 7
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 7
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 7
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- 150000003923 2,5-pyrrolediones Chemical class 0.000 claims description 4
- 108091022885 ADAM Proteins 0.000 claims description 4
- 108010091175 Matriptase Proteins 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 3
- 102100038078 CD276 antigen Human genes 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 108010065524 CD52 Antigen Proteins 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 102000002029 Claudin Human genes 0.000 claims description 3
- 108050009302 Claudin Proteins 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 101150016325 EPHA3 gene Proteins 0.000 claims description 3
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 3
- 101710088083 Glomulin Proteins 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 3
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 3
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 3
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 3
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 3
- 102000002698 KIR Receptors Human genes 0.000 claims description 3
- 108010043610 KIR Receptors Proteins 0.000 claims description 3
- 102000017578 LAG3 Human genes 0.000 claims description 3
- 101150030213 Lag3 gene Proteins 0.000 claims description 3
- 102000015728 Mucins Human genes 0.000 claims description 3
- 108010063954 Mucins Proteins 0.000 claims description 3
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
- 102000004473 OX40 Ligand Human genes 0.000 claims description 3
- 108010042215 OX40 Ligand Proteins 0.000 claims description 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 3
- 102100040120 Prominin-1 Human genes 0.000 claims description 3
- 102000014128 RANK Ligand Human genes 0.000 claims description 3
- 108010025832 RANK Ligand Proteins 0.000 claims description 3
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 3
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 102100038126 Tenascin Human genes 0.000 claims description 3
- 108010008125 Tenascin Proteins 0.000 claims description 3
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 3
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 3
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 3
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 3
- 102000006495 integrins Human genes 0.000 claims description 3
- 108010044426 integrins Proteins 0.000 claims description 3
- 229940051875 mucins Drugs 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 101150047061 tag-72 gene Proteins 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 46
- 125000000217 alkyl group Chemical group 0.000 description 33
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 28
- 125000003118 aryl group Chemical group 0.000 description 28
- 125000001424 substituent group Chemical group 0.000 description 27
- 125000000753 cycloalkyl group Chemical group 0.000 description 25
- 230000004913 activation Effects 0.000 description 23
- 125000000623 heterocyclic group Chemical group 0.000 description 23
- 125000001072 heteroaryl group Chemical group 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 125000003342 alkenyl group Chemical group 0.000 description 18
- 125000000304 alkynyl group Chemical group 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000001588 bifunctional effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 11
- 230000002411 adverse Effects 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 11
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 10
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 102000048776 human CD274 Human genes 0.000 description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 208000024799 Thyroid disease Diseases 0.000 description 6
- 230000007059 acute toxicity Effects 0.000 description 6
- 231100000403 acute toxicity Toxicity 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 230000008693 nausea Effects 0.000 description 6
- 229940066453 tecentriq Drugs 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 230000005909 tumor killing Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000005917 in vivo anti-tumor Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 3
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 208000006373 Bell palsy Diseases 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 206010012218 Delirium Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 3
- 206010021067 Hypopituitarism Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 206010060708 Induration Diseases 0.000 description 3
- 206010022004 Influenza like illness Diseases 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 3
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010035742 Pneumonitis Diseases 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 229910006069 SO3H Inorganic materials 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 3
- 206010047641 VIth nerve paralysis Diseases 0.000 description 3
- 206010047642 Vitiligo Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000022021 abducens nerve palsy Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- 206010003882 axonal neuropathy Diseases 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 208000018631 connective tissue disease Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 201000011486 lichen planus Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000005976 liver dysfunction Effects 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 201000005518 mononeuropathy Diseases 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 201000007540 subacute lymphocytic thyroiditis Diseases 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 101710158614 Interferon alpha/beta receptor 1 Proteins 0.000 description 2
- 101710158620 Interferon alpha/beta receptor 2 Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006585 (C6-C10) arylene group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940121530 balstilimab Drugs 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229940067219 cetrelimab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940011248 cosibelimab Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940121432 dostarlimab Drugs 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940121556 envafolimab Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000054261 human IFNAR1 Human genes 0.000 description 1
- 102000052179 human IFNAR2 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229940015183 manelimab Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940063500 penpulimab Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229940018007 retifanlimab Drugs 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229940018073 sasanlimab Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 229940121497 sintilimab Drugs 0.000 description 1
- 229940125310 socazolimab Drugs 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000034223 susceptibility to 2 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 229940121514 toripalimab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Provided herein are modified IFNα2b proteins and functional fragments thereof. Also provided are polypeptides, such as bi-functional and multi-functional ones, which further include a biological moiety such as an antibody or antigen-binding fragment thereof, as well as conjugates of such polypeptides.
Description
FIELD OF THE DISCLOSURE
The disclosure relates to modified IFNα2b proteins and functional fragments thereof, as well as multifunctional polypeptides and immunoconjugates comprising the IFNα2b or fragments.
Human IFNα2b belongs to type I interferons (IFNs-I) , which are clustered on chromosome 9p. It signals through a heterodimeric complex of interferon α/β receptor 1 (IFNAR1) and interferon α/β receptor 2 (IFNAR2) to elicit TYK2 and JAK1 activation, thereby triggering a cascade of immune related interferon stimulating genes (ISGs) which are critical for immune activation.
There is evidence showing that endogenous type I IFNs including IFNα2b can enhance the antitumor activity of chemotherapies, radiotherapies and some targeted therapies. Though recombinant IFNα2b has demonstrated efficacy for cancer treatment, such as melanoma, renal cell carcinoma and various hematological malignancies, patients on the therapy normally suffer from adverse effects, which present a significant challenge for the development of IFN-mediated therapeutics.
The present application addresses the clinical needs. Certain embodiments provide modified IFNα2b with reduced adverse effects and improved efficacy for clinical use.
In a first aspect, provided is an IFNα2b or a functional fragment thereof, wherein the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with interferon α/β receptor. In some embodiments, the interferon α/β receptor is selected from IFNAR1, IFNAR2, and the combination thereof.
In some embodiments, the binding affinity of the IFNα2b or the functional fragment thereof with the interferon α/β receptor is attenuated by at least 10 folds, 102 folds, 103 folds, 104 folds or 105 folds. In some embodiments, the IFNα2b or the functional fragment thereof is
modified to attenuate activation of Type I interferon signaling induced by the IFNα2b or the functional fragment thereof. In some embodiments, the activation of INFα signaling is attenuated by at least 10 folds, 102 folds, 103 folds, 104 folds, or 105 folds.
In some embodiments, the IFNα2b or the functional fragment thereof is modified by an amino acid substitution at one or more residues corresponding to the residues selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1. In some embodiments, the modification comprises an amino acid substitution at the residue corresponding to S152 of SEQ ID NO: 1. In some embodiments, the modification comprises an amino acid substitution with cysteine at the residue corresponding to S152 of SEQ ID NO: 1.
In some embodiments, the IFNα2b comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%or 100%sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
In some embodiments, the IFNα2b or the functional fragment thereof is modified by a chemical moiety.
In some embodiments, the chemical moiety comprises a structure of formula (I) :
R1-R2-R3-R4 (I) ,
R1-R2-R3-R4 (I) ,
wherein,
R1 is which is optionally further substituted with 1, 2 or 3 R*group (s) ;
L1 is selected from CH or N;
R1a is absent, or is selected from the group consisting of - (CH2) 0-3-C (O) -, - (CH2) 0-3-OC (O) -, and - (CH2) 0-3-NHC (O) -;
each R1b is independently absent, or is independently selected from the group consisting of -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-, -NH-C1-6 alkyl-, -O-C1-6 alkyl-, -C (O) -C1-6 alkyl-, -OC (O) -C1-6 alkyl-, -C (O) O-C1-6 alkyl-and -C (O) NH-C1-6 alkyl-;
each R1c is independently selected from the group consisting of H, C1-6 alkyl, and C1-6 haloalkyl;
m is an integer in a range of 1 to 30000;
R*is selected from H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, or C2-6 alkynyl;
R2 is a linker which is cleavable under tumor environment;
R3 is
X is selected from -NH-or -O-;
Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, -C (O) -C (O) -or -NHC (O) -;
each Rx and Ry is independently selected from H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl;
n is 0, 1, 2, 3, 4, or 5;
R4 is
Ra and Rb are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxyl;
R4a is absent, or is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-, (C1-6 alkylene-O) p- (CH2) 1-12, - (CH2) 1-12-C3-8 cycloalkylene-, - (CH2) 1-12-C3-8 cycloalkylene- (CH2) 1-12, - (CH2) 1-12-C6-10 arylene-, and - (CH2) 1-12-C6-10 arylene- (CH2) 1-12;
R4a is optionally further substituted with 1, 2, 3, 4 or 5 R#group (s) ;
R4b is selected from the group consisting of -NH-, -O-, -C (O) -, -C (O) O-, -OC (O) -, -C (O) -C (O) -, -C (O) NH-or -NHC (O) -;
R#is selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl or C2-6 alkynyl;
p is 1, 2, 3, 4 or 5;
wherein R3 links to R2 via the X of R3, and links to R4 via the Y of R3.
In some embodiments, R1 is which is optionally further substituted with 1, 2 or 3 R*group (s) ;
L1 is selected from CH or N;
R1a is absent, or is selected from the group consisting of -C (O) -, -OC (O) -, and -NHC (O) -;
each R1b is independently absent, or is independently selected from the group consisting of -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-, -NH-C1-4 alkyl-, -O-C1-4 alkyl-, -C (O) -C1-4 alkyl-, -OC (O) -C1-4 alkyl-, -C (O) O-C1-4 alkyl-and -C (O) NH-C1-4 alkyl-;
each R1c is independently selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl;
each m is independently an integer in a range of 1 to 5000;
R*is selected from H, halogen, C1-6 alkyl or C1-6 haloalkyl;
alternatively, R1 is which is optionally further substituted with 1, 2 or 3 R*group (s) ;
R1a is absent, or is -C (O) -;
R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl;
m is an integer in a range of 1 to 3000;
R*is selected from H, halogen or C1-4 alkyl;
still alternatively, R1 is R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500; yet alternatively, R1 is a linear polyethylene glycol having a molecular weight of about 20000.
In some embodiments, R2 is selected from the group consisting of matrix metalloprotease (MMP) cleavable linker, a disintegrin and metalloprotease domain-containing (ADAM) metalloprotease cleavable linker, a prostate specific antigen (PSA) protease cleavable linker, a urokinase-type plasminogen activator (uPA) protease cleavable linker, a membrane type serine protease 1 (MT-SP1) protease cleavable linker, a matriptase protease cleavable linker (ST14) and a legumain protease cleavable linker.
In some embodiments, R2 is a matrix metalloprotease (MMP) cleavable linker and comprises an amino acid sequence of anyone selected from SEQ ID NO: 21-35. In some embodiments, R2 is a prostate specific antigen (PSA) protease cleavable linker and comprises an amino acid sequence of anyone selected from SEQ ID NO: 14-16. In some embodiments, R2 is urokinase-type plasminogen activator (uPA) protease cleavable linker and comprises an amino acid sequence of anyone selected from SEQ ID NO: 11-13. In some embodiments, R2 is a legumain protease cleavable linker and comprises an amino acid sequence of any one selected from SEQ ID NOs: 18-19 or AAN or Cbz-AAN-AMC. “Cbz” and “AMC” in Cbz-AAN-AMC represent benzyloxycarbonyl and 7-amino-4-methylcoumarin, respectively.
In some embodiments, the chemical moiety comprises a structure of formula (II) :
wherein R1, R3 and R4 are as defined above.
In some embodiments, R3 is
wherein,
X is selected from -NH-or -O-;
Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -;
each Rx and Ry is independently selected from H, halogen, C1-4 alkyl or C1-4 haloalkyl;
n is 0, 1, 2 or 3;
alternatively,
R3 is
X is selected from NH or O;
Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -.
In some embodiments, the chemical moiety comprises a structure of formula (III) :
wherein,
X is selected from NH or O;
Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -;
wherein R1, R2 and R4 are as defined above.
In some embodiments, the chemical moiety comprises a structure of formula (IV) :
wherein R1 and R4 are as defined above.
In some embodiments,
R4 is
Ra and Rb are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxyl;
R4a is absent, or is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-, (C1-6 alkylene-O) p- (CH2) 1-12, - (CH2) 1-12-C3-8 cycloalkylene- and - (CH2) 1-12-C3-8 cycloalkylene- (CH2) 1-12;
R4a is optionally further substituted with 1, 2, 3 or 4 R#group (s) ;
R4b is -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-or -NHC (O) -;
R#is selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl;
p is 1, 2, 3 or 4;
alternatively,
Ra and Rb are each independently selected from the group consisting of H and C1-4 alkyl;
R4a is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-and (C1-4 alkylene-O) p- (CH2) 1-12;
R4a is optionally further substituted with 1, 2 or 3 R#group (s) ;
R4b is -NH-, -O-or -C (O) -;
R#is selected from the group consisting of H, halogen, C1-6 alkyl and C1-6 haloalkyl;
p is 1, 2 or 3;
still alternatively,
Ra and Rb are H;
R4a is - (CH2) 2-12-;
R4b is -NH-;
R4a is optionally further substituted with 1 or 2 R#group (s) ;
R#is selected from the group consisting of H, halogen and C1-4 alkyl.
In some embodiments, the chemical moiety comprises a structure of formula (V) :
wherein R1, R2 and R3 are as defined above.
In some embodiments, the chemical moiety comprises a structure of formula (VI) :
wherein, the PEGm is R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500.
In some embodiments, the PEGm is a linear polyethylene glycol having a molecular weight of about 20000.
In some embodiments, the IFNα2b or the functional fragment thereof is modified by the chemical moiety at a residue corresponding to the residue selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1.
In some embodiments, the IFNα2b or the functional fragment thereof comprises an amino acid substitution with a cysteine at a position corresponding to the position selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1, and the chemical moiety is linked to the IFNα2b or the functional fragment via the cysteine.
In some embodiments, the R4 of the chemical moiety is linked to the S atom of the cysteine residue via a maleimide, an acetylene, a vinyl, a mono-substituted butenedioic acid, or a disubstituted maleimide.
In some embodiments, the IFNα2b or the functional fragment thereof is conjugated to a biomolecule specifically binding to a target. In some embodiments, the IFNα2b or the
functional fragment thereof is conjugated to the biomolecule directly. In some embodiments, the IFNα2b or the functional fragment thereof is conjugated to the biomolecule via a linker.
In some embodiments, the biomolecule comprises an antibody or an antigen binding fragment thereof. In some embodiments, the antibody or the antigen binding fragment thereof is selected from the group consisting of a full-length antibody, a Fab, Fab’, a F (ab’) 2, a Fd, a Fd’, a Fv, a scFv, a ds-scFv, a sdAb and a nanobody.
In some embodiments, the target is PD-L1 or PD-1. In some embodiments, the biomolecule comprises a sdAb comprising a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6, and the CDR1, CDR2 and CDR3 are according to Kabat numbering scheme. In some embodiments, the biomolecule comprises a sdAb comprising:
(i) a CDR1 comprising the amino acid sequence of FRHYVMG (SEQ ID NO: 3) ,
(ii) a CDR2 comprising the amino acid sequence of AISWSGSGSYYADSVKG (SEQ ID NO: 4) , and
(iii) a CDR3 comprising the amino acid sequence of DMTTRMSQASREYDY (SEQ ID NO: 5) .
In some embodiments, the biomolecule comprises a sdAb, and the sdAb comprises a sequence having at least 80%identity with SEQ ID NO: 6.
In some embodiments, the target is PD-L1 or PD-1. In some embodiments, the biomolecule comprises a sdAb comprising a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6, and the CDR1, CDR2 and CDR3 are according to Kabat numbering scheme. In some embodiments, the biomolecule comprises a sdAb comprising:
(i) a CDR1 comprising the amino acid sequence of SGTQFSDSKID (SEQ ID NO: 50) ,
(ii) a CDR2 comprising the amino acid sequence of GIFQTGSTIYEDSVKG (SEQ ID NO: 51) , and
(iii) a CDR3 comprising the amino acid sequence of IGRGTLA (SEQ ID NO: 52) .
In some embodiments, the biomolecule comprises a sdAb, and the sdAb comprises a sequence having at least 80%identity with SEQ ID NO: 49.
In some embodiments, the biomolecule further comprises a Fc region.
In some embodiments, the IFNα2b comprises the amino acid sequence having at least 80%identity with SEQ ID NO: 1 or SEQ ID NO: 2.
Also provided, in some embodiments, is a multi-functional polypeptide, comprising an IFNα2b or a functional fragment thereof of the present disclosure, and an antibody or antigen-binding fragment thereof. In some embodiments, the multi-functional polypeptide includes a single copy of the IFNα2b or functional fragment thereof. In some embodiments, the multi-functional polypeptide comprises an Fc fragment.
In some embodiments, the IFNα2b or a functional fragment thereof is disposed on the C-terminal side of the Fc fragment. In some embodiments, the antibody or antigen-binding fragment thereof is disposed on the N-terminal side of the Fc fragment. In some embodiments, the Fc fragment comprises knob-in-hole substitutions as compared to the corresponding wild-type Fc fragment.
In some embodiments, the antibody or antigen-binding fragment thereof has specificity to a tumor associated antigen or immune checkpoint protein. In some embodiments, the tumor associated antigen is selected from the group consisting of EGFR, Her2, EpCAM, CD20, CD30, CD33, CD47, CD52, CD133, CD73, CEA, gpA33, Mucins, TAG-72, CIX, PSMA, folate-binding protein, GD2, GD3, GM2, VEGF, VEGFR, Integrin, αVβ3, α5β1, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP, Tenascin, and Claudin 18.2.
In some embodiments, the immune checkpoint protein is selected from the group consisting of PD-1, PD-L1, CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX-40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM, BTLA, KIR, and CD47. In some embodiments, antibody or antigen-binding fragment thereof is an anti-PD-L1 or anti-PD-1 single domain antibody (sdAb) .
Also provided, in one embodiment, is an immunoconjugate comprising a multi-functional polypeptide of the present disclosure, conjugated with a chemical moiety.
In some embodiments, the chemical moiety comprises a structure of formula (VI) :
wherein, the PEGm is R1c is selected from the group consisting of H, C1-4
alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500; alternatively, the PEGm is a linear polyethylene glycol having a molecular weight of about 20000.
In some embodiments, the immunoconjugate further comprises a Fc region.
In a third aspect, provided is a polynucleotide encoding the polypeptide of any one of the present application, or the immunoconjugate of the present application.
In a fourth aspect, provided is a vector comprising the polynucleotide of the present application.
In a fifth aspect, provided is a host cell comprising the vector of the present application.
In a sixth aspect, provided is a pharmaceutical composition comprising the polypeptide, the immunoconjugate, or the polynucleotide of the present application.
In a seventh aspect, provided is a method for treating a disorder in a subject in need thereof, comprising administrating an effective amount of the polypeptide, the immunoconjugate, or the nucleic acid of the present application to the subject. In some embodiments, the disorder is cancer.
It is to be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present disclosure. These and other aspects of the disclosure will become apparent to one of skill in the art. These and other embodiments of the disclosure are further described by the detailed description that follows.
BRIEF DESCRIPTIONS OF THE DRAWINGS
FIG. 1 illustrates exemplary immunoconjugates of the present application in different formats.
FIG. 2A-2B illustrate an exemplary structure of the immunoconjugates of the present application comprising an IFNα2b modified by a chemical moiety, and SDS-PAGE of the immunoconjugate.
FIG. 3A-3B illustrate binding affinity of the immunoconjugates of the present application with PD-L1.
FIG. 4 illustrates activation of PD-1/PD-L1 signaling by the immunoconjugates of the present application.
FIG. 5A-5B illustrate binding affinity of the immunoconjugates of the present application with IFN receptors.
FIG. 6A-6B illustrate activation of Type I interferon signaling by the immunoconjugates of the present application.
FIG. 7A-7B illustrate a system for evaluating in vitro anti-tumor efficacy, and the in vitro tumor killing efficacy of the immunoconjugates of the present application.
FIG. 8 illustrates in vivo tumor inhibition of the immunoconjugates of the present application.
FIG. 9 illustrates toxicology analysis of the immunoconjugates of the present application.
FIG. 10 illustrate the structures of two bi-functional polypeptides.
FIG. 11 shows the activity testing results for the bi-functional polypeptides and their counterpart immunoconjugates with respect to binding to interferon receptors.
FIG. 12 shows the activity testing results for the bi-functional polypeptides and their counterpart immunoconjugates with respect to inhibition of PD-L1/PD-1 signaling.
FIG. 13 shows the in vivo tumor inhibition activities of these bi-functional polypeptides and their counterpart immunoconjugates in a SCID RKO animal model.
Definitions
Before describing the embodiments in detail, it is to be understood that the present disclosure is not limited to particular compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
As used in this specification and the appended claims, the singular forms “a” , “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a molecule” optionally includes a combination of two or more such molecules, and the like.
The term “about” as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
It is understood that aspects and embodiments of the present disclosure include “comprising, ” “consisting, ” and “consisting essentially of” aspects and embodiments.
As used herein, the term “antibody” is used in the broadest sense and specifically covers intact antibodies (e.g., full length antibodies) , antibody fragments (including without limitation Fab, F (ab’) 2, scFv, scFv-Fc, single domain antibodies (sdAb, also known as nanobody) , single heavy chain antibodies, and single light chain antibodies) , monoclonal antibodies, and polyclonal antibodies, so long as they exhibit the desired biological activity (e.g., epitope binding) .
As used herein, the term “isolated” antibody may refer to an antibody that is substantially free of other cellular material. In one embodiment, an isolated antibody is substantially free of other proteins from the same species. In another embodiment, an isolated antibody is expressed by a cell from a different species and is substantially free of other proteins from the different species. In some embodiments, an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. An antibody may be rendered substantially free of naturally associated components (or components associated with the cellular expression system used to produce the antibody) by isolation, using protein purification techniques well known in the art. In some embodiments, the antibody will be purified (1) to greater than 75%by weight of antibody as determined by the Lowry method, and most preferably more than 80%, 90%, 95%or 99%by weight, or (2) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody’s natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
As used herein, the term “native antibodies and immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one
covalent disulfide bond (also termed a “VH/VL pair” ) , while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light-and heavy-chain variable domains. See, e.g., Chothia et al., J. Mol. Biol., 186: 651 (1985) ; Novotny and Haber, Proc. Natl. Acad. Sci. U.S.A., 82: 4592 (1985) .
As used herein, the term “variable” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR) . The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a β-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991) . The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity. Variable region sequences of interest include the humanized variable region sequences for CD47 antibodies described in detail elsewhere herein.
The term “hypervariable region (HVR) ” or “complementarity determining region (CDR) ” may refer to the subregions of the VH and VL domains characterized by enhanced sequence variability and/or formation of defined loops. These include three CDRs in the VH domain (H1, H2, and H3) and three CDRs in the VL domain (L1, L2, and L3) . H3 is believed to be critical in imparting fine binding specificity, with L3 and H3 showing the highest level of diversity. See Johnson and Wu, in Methods in Molecular Biology 248: 1-25 (Lo, ed., Human
Press, Totowa, N.J., 2003) .
A number of CDR/HVR delineations are known. The Kabat Complementarity Determining Regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991) ) . Chothia refers instead to the location of the structural loops (Chothia and Lesk J. Mol. Biol. 196: 901-917 (1987) ) . The AbM HVRs represent a compromise between the Kabat HVRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software. The “contact” HVRs are based on an analysis of the available complex crystal structures. The residues from each of these HVRs/CDRs are noted below. “Framework” or “FR” residues are those variable domain residues other than the HVR/CDR residues
“Extended” HVRs are also known: 24-36 or 24-34 (L1) , 46-56 or 50-56 (L2) and 89-97 or 89-96 (L3) in the VL and 26-35 (H1) , 50-65 or 49-65 (H2) and 93-102, 94-102, or 95-102 (H3) in the VH (Kabat numbering) .
“Numbering according to Kabat” may refer to the numbering system used for heavy chain variable domains or light chain variable domains of the compilation of antibodies in Kabat et al., supra. The actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or HVR of the variable domain. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence. Typically, the Kabat numbering is used when referring to a residue in the variable domains (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) , whereas the EU numbering system or index (e.g., the EU index as in Kabat, numbering according to EU IgG1) is generally used when referring to a residue in the heavy chain constant
region.
As used herein, the term “antibody fragment” , and all grammatical variants thereof, are defined as a portion of an intact antibody comprising the antigen binding site or variable region of the intact antibody which, in certain instances, is free of the constant heavy chain domains (i.e. CH2, CH3, and/or CH4, depending on antibody isotype) of the Fc region of the intact antibody. Examples of antibody fragments include Fab, Fab’, Fab’-SH, F (ab’) 2, and Fv fragments; diabodies; any antibody fragment that is a polypeptide having a primary structure consisting of one uninterrupted sequence of contiguous amino acid residues (referred to herein as a “single-chain antibody fragment” or “single chain polypeptide” ) , including without limitation (1) single-chain Fv (scFv) molecules, (2) single chain polypeptides containing only one light chain variable domain, or a fragment thereof that contains the three CDRs of the light chain variable domain, without an associated heavy chain moiety, and (3) single chain polypeptides containing only one heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety. In an antibody fragment comprising one or more heavy chains, the heavy chain (s) can contain any constant domain sequence (e.g. CH1 in the IgG isotype) found in a non-Fc region of an intact antibody, and/or can contain any hinge region sequence found in an intact antibody, and/or can contain a leucine zipper sequence fused to or situated in the hinge region sequence or the constant domain sequence of the heavy chain (s) .
The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab’ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab’-SH is the designation herein for Fab’ in which the cysteine residue (s) of the constant domains bear a free thiol group. F (ab’) 2 antibody fragments originally were produced as pairs of Fab’ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
A single-domain antibody (sdAb) , also known as a nanobody, is an antibody fragment consisting of a single monomeric variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen. With a molecular weight of only 12-15 kDa, single-domain antibodies are much smaller than common antibodies (150-160 kDa) which are composed of two heavy protein chains and two light chains, and even smaller than Fab fragments (~50 kDa, one light chain and half a heavy chain) and single-chain variable fragments (~25 kDa, two variable domains, one from a light and one from a heavy chain) . The first
single-domain antibodies were engineered from heavy-chain antibodies found in camelids; these are called VHH fragments.
The term “specific binding” as used herein refers to that the binding is selective for the antigen/receptor and can be discriminated from unwanted or non-specific interactions. The ability of the binding pair can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques known to the art, e.g. Surface Plasmon Resonance (SPR) technique (analyzed on a BIACORE instrument) , and additional binding assays. In some embodiments, the extent of binding of an antibody/cytokine to an unrelated protein is less than about 10%of the binding to the antigen/receptor as measured, e.g. by SPR. In some embodiments, an immunoglobulin/cytokine that binds to the antigen/receptor has a dissociation constant (KD) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10-8 M or less, e.g. from 10-8 M to 10-13 M, e.g. from 10-9 M to 10-13 M) .
As used herein, the term “affinity” or “binding affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g. an antibody or cytokine) and its binding partner (e.g. an antigen or receptor) . Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1: 1 interaction between members of a binding pair (e.g. antibody and antigen) . The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD) , which is the ratio of dissociation and association rate constants (koff and kon, respectively) . Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein.
“Reduced binding” , for example reduced binding to an IFN receptor, refers to a decrease in affinity for the respective interaction, as measured for example by SPR or ELISA. For clarity, the term also includes reduction of the affinity to zero (or below the detection limit of the analytic method) , i.e. complete abolishment of the interaction. Conversely, “increased binding” refers to an increase in binding affinity for the respective interaction.
As used herein, the term “treatment” refers to clinical intervention designed to alter the natural course of the individual or cell being treated during the course of clinical pathology. Desirable effects of treatment include decreasing the rate of disease progression, ameliorating or palliating the disease state, and remission or improved prognosis. For example, an individual
is successfully “treated” if one or more symptoms associated with cancer are mitigated or eliminated, including, but are not limited to, reducing the proliferation of (or destroying) cancerous cells, decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, and/or prolonging survival of individuals. In some embodiments, “treating” a disease such as cancer refers to delaying progression of the disease, i.e., deferring, hindering, slowing, retarding, stabilizing, and/or postponing development of the disease (such as cancer) . This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, a late stage cancer, such as development of metastasis, may be delayed.
As used herein, the term “percent (%) amino acid sequence identity” with respect to a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known to the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
As used herein, the term “substituting” or “substitution of an amino acid” as used herein refers to substituting the original amino acid residue for one or more other amino acid residue (s) .
An “effective amount” is at least the minimum amount required to effect a measurable improvement or prevention of a particular disease (e.g., cancer) . An effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of a therapeutic agent (or combination of therapeutic agents) to elicit a desired response in the individual. An effective amount is also one in which any toxic or detrimental effects of the treatment are outweighed by the therapeutically beneficial effects. For therapeutic use, beneficial or desired results include clinical results such as decreasing one or more symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, enhancing effect
of another medication such as via targeting, delaying the progression of the disease, and/or prolonging survival. In the case of cancer or tumor, an effective amount of the drug may have the effect in reducing the number of cancer cells; reducing the tumor size; inhibiting (i.e., slow to some extent or desirably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and desirably stop) tumor metastasis; inhibiting to some extent tumor growth; and/or relieving to some extent one or more of the symptoms associated with the disorder. An effective amount can be administered in one or more administrations. For purposes of this disclosure, an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish therapeutic treatment either directly or indirectly. As is understood in the clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective amount” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
As used herein, the term “drug antibody ratio” or “DAR” , refers to the number of chemical moieties conjugated to a polypeptide of the instant disclosure. For instance, when DAR is 1 (DAR1) , a single chemical moiety is conjugated to one of the chains of a bifunctional polypeptide of the instant disclosure, on average. Likewise, when DAR is 2 (DAR2) , an average of two chemical moieties are conjugated to the bifunctional polypeptide of the instant disclosure. The DAR can range from 1 to 4, although higher loads, e.g., 10, are also possible depending on the number of linkage site in the polypeptide.
As used herein, the term “subject” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs.
Interferons and Attenuated Interferons
Interferons (IFNs) belong to the large class of proteins known as cytokines, molecules used for communication between cells to trigger the protective defenses of the immune system. IFNs are named for their ability to “interfere” with viral replication by protecting cells from virus infections. They also have various other functions, including activating immune cells such as natural killer cells and macrophages, and increasing host defenses by up-regulating antigen presentation by virtue of increasing the expression of major histocompatibility complex (MHC)
antigens.
More than twenty distinct IFN genes and proteins have been identified in animals, including humans. They are typically divided among three classes: Type I IFN, Type II IFN, and Type III IFN. Human IFNα2b belongs to Type I IFN, which are clustered on chromosome 9p. It signals through a heterodimeric complex of interferon α/β receptor 1 (IFNAR1) and interferon α/β receptor 2 (IFNAR2) to elicit TYK2 and JAK1 activation, thereby triggers a cascade of immune related interferon stimulating genes (ISGs) which are critical for immune activation.
Several different types of interferon therapy have been approved for use in humans. For example, in January 2001, the Food and Drug Administration (FDA) approved Pegintron, a PEGylated interferon-alpha-2b. Approval for Pegasys, a PEGylated interferon-alpha-2a, followed in October 2002. The PEGylated drug could prolong in vivo half-life of interferon, and can be injected once weekly, rather than administering two or three times per week as is necessary for conventional interferon-alpha. When used with the antiviral drug ribavirin, PEGylated interferon is effective in treatment of hepatitis C. Interferon therapy has been developed and used in combination with chemotherapy and radiation as a treatment for some cancers, including hematological malignancy such as leukemia and lymphomas, chronic myeloid leukemia, nodular lymphoma, and cutaneous T-cell lymphoma, as well as melanomas. However, patients on the therapy normally suffer from adverse effects. Therefore, modified IFNα2b with reduced adverse effects and improved efficacy is in need in clinical.
In one aspect, provided herein is an IFNα2b or a functional fragment thereof that is modified to attenuate activity. As demonstrated in the experimental examples, such attenuated IFNα2b or functional fragments thereof not only had greatly improved safety, they also demonstrated excellent treatment effects. In fact, when adopted into a bifunctional polypeptide that further contained an PD-L1 moiety, the resulting molecule (e.g., 112_08-IFM-knob) demonstrated superior in vivo anti-tumor activities over Tecentriq in combination with PEGylated interferon alpha (Tecentriq +PEG-IFNa) (see, e.g., FIG. 12) .
Accordingly, in one embodiment of the present disclosure, provided is a modified IFNα2b (as compared to the wild-type IFNα2b protein, such as the human IFNα2b protein) or a functional fragment thereof that has reduced binding affinity to interferon α/β receptor. In some embodiments, the interferon α/β receptor is selected from IFNAR1, IFNAR2, and the
combination thereof. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with IFNAR1. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with IFNAR2. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with IFNAR1 and IFNAR2.
In some embodiments, the IFNα2b or the functional fragment thereof is attenuated such that its affinity to the interferon α/β receptor is attenuated by at least about 10 folds, at least about 102 folds, at least about103 folds, at least about 104 folds, or at least about 105 folds. In some embodiments, the binding affinity of the IFNα2b or the functional fragment thereof with IFNAR1 is reduced by at least about 10 folds, at least about 102 folds, at least about103 folds, at least about 104 folds or at least about 105 folds. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with IFNAR2 by at least about 10 folds, at least about 102 folds, at least about103 folds, at least about 104 folds or at least about 105 folds. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with IFNAR2 by at least about 10 folds. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with IFNAR2 by at least about 102 folds. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with IFNAR2 by at least about103 folds. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with both IFNAR1 and IFNAR2 by at least about 10 folds, at least about 102 folds, at least about103 folds, at least about 104 or at least about 105 folds.
In some embodiments, the binding affinity of the IFNα2b or the functional fragment thereof with interferon α/β receptor is attenuated to reduce adverse effect of the IFNα2b or the functional fragment thereof after administration to a subject in need thereof. In some embodiments, the adverse effect includes acute toxicity, subacute side effect and chronic side effect. In some embodiments, the acute toxicity includes the flu-like symptoms such as fever, chills, myalgia, headache, and nausea. In some embodiments, the subacute side effect includes but is not limited to hematological side effects such as anemia, decrease in leukocyte and platelet counts and decreased platelet aggregation; hepatic side effects such as raised
transaminases and inhibition of cytochrome P450 enzymes; gastro-intestinal side effects such as loss of appetite, nausea, vomiting and diarrhea; psychiatric side effects such as depression, difficulties in cognition and delirium; neurological side effects such as seizures, neuropathies, multiple-sclerosis like disease and mysthenia gravis; renal side effects such as proteinuria; cardiovascular side effects such as arrythmias, ischemic heart disease, cardiomyopathy and retinal abnormalities; pulmonary side effects such as pneumonitis; endocrine side effects such as thyroid disorder, diabetes mellitus, decrement of sex hormone levels and hypopituitarism; dermatological side effects such as alopecia, erythema and induration at injection site, rash, pruritus, vitiligo, lichen planus, psoriasis.
In some embodiments, the side effect includes autoimmune disorders such as thyroid disorder, liver dysfunction, connective tissue diseases, dermatological disorders, hematologic disorders, neurological disorders, pulmonary disorder and metabolic disorder. In some embodiments, the side effect results in disorders including but not limited to subacute lymphocytic thyroiditis, graves’ disease, permanent hypothyroidism, autoimmune hepatitis, primary biliary cirrhosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, leucocytoclastic vasculitis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, inflammatory demyelinating polyneuropathy, multiple sclerosis-like disease, axonal neuropathy and hearing loss, bell’s palsy, mononeuropathy multiplex, myasthenia gravis, abducent nerve paralysis, interstitial pneumonitis and diabetes mellitus.
In another aspect, provided herein is a polypeptide comprising an IFNα2b or a functional fragment thereof, wherein the IFNα2b or the functional fragment thereof is modified to attenuate activation of Type I interferon signaling induced by the IFNα2b or the functional fragment thereof. In some embodiments, the activation of INFα signaling is attenuated by at least 10 folds, 102 folds, 103 folds, 104 or 105 folds. In some embodiments, the activation of INFα signaling is attenuated by at least 102 folds. In some embodiments, the activation of INFα signaling is attenuated by at least 103 folds. In some embodiments, the activation of INFα signaling is attenuated by at least 104 folds.
In some embodiments, the activation of Type I interferon signaling is attenuated to reduce adverse effect of the IFNα2b or the functional fragment thereof after administration to a subject in need thereof. In some embodiments, the adverse effect includes acute toxicity, subacute side effect and chronic side effect. In some embodiments, the acute toxicity includes the flu-like symptoms such as fever, chills, myalgia, headache, and nausea. In some
embodiments, the subacute side effect includes but is not limited to hematological side effects such as anemia, decrease in leukocyte and platelet counts and decreased platelet aggregation; hepatic side effects such as raised transaminases and inhibition of cytochrome P450 enzymes; gastro-intestinal side effects such as loss of appetite, nausea, vomiting and diarrhea; psychiatric side effects such as depression, difficulties in cognition and delirium; neurological side effects such as seizures, neuropathies, multiple-sclerosis like disease and mysthenia gravis; renal side effects such as proteinuria; cardiovascular side effects such as arrythmias, ischemic heart disease, cardiomyopathy and retinal abnormalities; pulmonary side effects such as pneumonitis; endocrine side effects such as thyroid disorder, diabetes mellitus, decrement of sex hormone levels and hypopituitarism; dermatological side effects such as alopecia, erythema and induration at injection site, rash, pruritus, vitiligo, lichen planus, psoriasis.
In some embodiments, the side effect includes autoimmune disorders such as thyroid disorder, liver dysfunction, connective tissue diseases, dermatological disorders, hematologic disorders, neurological disorders, pulmonary disorder and metabolic disorder. In some embodiments, the side effect results in disorders including but not limited to subacute lymphocytic thyroiditis, graves’ disease, permanent hypothyroidism, autoimmune hepatitis, primary biliary cirrhosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, leucocytoclastic vasculitis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, inflammatory demyelinating polyneuropathy, multiple sclerosis-like disease, axonal neuropathy and hearing loss, bell’s palsy, mononeuropathy multiplex, myasthenia gravis, abducent nerve paralysis, interstitial pneumonitis and diabetes mellitus.
In some embodiments, the IFNα2b or the functional fragment thereof is modified to improve the performance of the polypeptide after administration to a subject in need thereof. In some embodiments, the performance includes but is not limited to pharmacokinetics (PK) , pharmacodynamics (PD) , efficacy, and safety. In some embodiments, the efficacy includes anti-tumor efficacy. In some embodiments, the anti-tumor efficacy includes but is not limited to inhibiting tumor growth, reducing tumor volume, increasing survival of a subject and inducing protection against tumor recurrence.
In some embodiments, the modification includes introducing an amino acid mutation to wild type IFNα2b (SEQ ID NO: 1) . The term “amino acid mutation” as used herein is meant to encompass amino acid substitutions, deletions, insertions, and modifications. Any combination of substitution, deletion, insertion, and modification can be made to arrive at the polypeptide of
the present application, provided that the polypeptide possesses the desired characteristics, e.g., reduced binding to IFNAR1 and/or IFNAR2, or reduced activation of Type I interferon signaling.
In some embodiments, the amino acid mutations are amino acid substitutions. In some embodiments, the polypeptide of the present application is obtained by replacing one amino acid with another amino acid having different structural and/or chemical properties. In some embodiments, the amino acid substitutions include replacing a hydrophobic by a hydrophilic amino acid. In some embodiments, the amino acid substitutions include replacement by non-naturally occurring amino acids or by naturally occurring amino acid derivatives of the twenty standard amino acids (e.g. 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine) . Standard amino acids, the abbreviations and the properties thereof are as listed in Table 1 below.
Table 1. Standard amino acids
It is contemplated that amino acid residues on the binding interface of IFNα2b to its binding target play important roles in the binding. Accordingly, substitution of one or more of such residues to a non-conservative amino acid can attenuate the binding affinity or biological activity of IFNα2b. Amino acid residues on the binding interface of IFNα2b are known. For instance, Thomas et al. “Structural linkage between ligand discrimination and receptor activation by type I interferons, ” Cell (2011) 146 (4) : 621-32 reported that residues R12, L15,
M16, R22, L26, F27, L30, R33, H34, D35, A145, M148, R149, S152, L153, and N156 are located on the binding interface.
In some embodiments, the IFNα2b or the functional fragment thereof of the present disclosure includes an amino acid substitution at one or more residues of R12, L15, M16, R22, L26, F27, L30, R33, H34, D35, A145, M148, R149, S152, L153, and N156 (location according to SEQ ID NO: 1) . In some embodiments, the substitution is a non-conservative substitution. In some embodiments, the substitution is with cysteine (C) which has the added benefit of serving as the site for conjugation.
In some embodiments, it is contemplated that substitutions at residues C29, D35, R144, or E146 of SEQ ID NO: 1 can achieve the same purpose. In some embodiments, therefore, the IFNα2b or the functional fragment thereof is modified by an amino acid substitution at C29, D35, R144, or E146 of SEQ ID NO: 1. In some embodiments, the substitution is a non-conservative substitution.
In some embodiments, the IFNα2b or the functional fragment thereof is modified at the residue corresponding to S152 of SEQ ID NO: 1. In some embodiments, the IFNα2b or the functional fragment thereof is modified by an amino acid substitution at S152 of SEQ ID NO: 1. In some embodiments, the modification comprises an amino acid substitution with cysteine (C) at S152 of SEQ ID NO: 1.
In some embodiments, the IFNα2b or fragment thereof comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identity with the sequence of SEQ ID NO: 1. In some embodiments, the IFNα2b comprises an amino acid sequence of SEQ ID NO: 1. In some embodiments, the IFNα2b comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identity with the sequence of SEQ ID NO: 2. In some embodiments, the IFNα2b comprises an amino acid sequence of SEQ ID NO: 2.
In some embodiments, the IFNα2b or fragment thereof comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identity with the sequence of SEQ ID NO: 1, while retaining any one or more of the substitutions as disclosed herein. For instant, the amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identity with the sequence of SEQ ID NO: 1 includes one or more substitutions at R12, L15, M16, R22, L26, F27, L30,
R33, H34, D35, A145, M148, R149, S152, L153, and/or N156 of SEQ ID NO: 1. In some embodiments, the substitution is with a cysteine (C) residue. In some embodiments, the amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%identity with the sequence of SEQ ID NO: 1 includes a cysteine (C) residue at residue 152.
Multi-Functional Polypeptides
It is demonstrated herein that the modified IFNα2b or the functional fragment thereof can be suitably incorporated into a bi-for multi-functional polypeptide that includes one or more biological moieties, such as antibodies and cytokines.
In a particular embodiment, multifunctional polypeptide includes one or more of the IFNα2b or the functional fragment thereof and one or more antibodies. In some embodiments, the multifunctional polypeptide further includes an Fc fragment, such as a human IgG1, IgG2, IgG3 or IgG4 Fc (CH2 and CH3) . Multiple formats of these multifunctional polypeptides have been tested, as illustrated in FIG. 1 and 10.
In one embodiment, the multifunctional polypeptide is symmetric and includes two identical polypeptide chains. Each chain includes an antibody or antigen-binding fragment, a Fc portion, and an IFNα2b or the functional fragment thereof. In some embodiments, in each peptide chain, both the antibody/fragment and the IFNα2b or the functional fragment thereof are located at the N-terminal side of the Fc fragment (Format 1) . In some embodiments, the antibody/fragment is located at the N-terminal side of the Fc fragment, while the IFNα2b or the functional fragment thereof is located at the C-terminal side of the Fc fragment (Format “L1IF” ) .
In one embodiment, the multifunctional polypeptide is asymmetric and includes two polypeptide chains that have different sequences. In some of aspects of this embodiment, the multifunctional polypeptide includes just one copy of the IFNα2b or the functional fragment thereof. In other words, only one peptide chain includes the IFNα2b or the functional fragment thereof, while the other peptide chain does not. In some of these asymmetric formats, e.g., Formats 2 and 3, the single copy of the IFNα2b or the functional fragment thereof is located at the C-terminal side of one of the two chains of the Fc fragment, while each chain further contains an antibody/fragment at the N-terminal end. Knob-in-hole substitutions can be made to improve proper pairing of these asymmetric peptides.
In Formats 3-5, the single copy of the IFNα2b or the functional fragment thereof is
placed at the N-terminal side of the Fc fragment, either between one of the antibodies/fragments and the Fc (Format 6) , or the far N-terminal side of both (Format 5) , or the Fc (Format 4) .
The symmetric format “L1IF” proved to an excellent format, demonstrating potent in vitro and in vivo activities with excellent safety profile (Examples 2-9) . Formats 1 and 2 (asymmetric with a single IFNα2b or fragment at the C-terminal side of the Fc) exhibited even greater anti-tumor activities (see, e.g., FIG. 13) , including polypeptides alone, or further with conjugated chemical moieties.
In accordance with one embodiment of the present disclosure, therefore, provided is a multi-functional polypeptide that includes an IFNα2b or a functional fragment thereof of the present disclosure and an antibody or antigen-binding fragment thereof. In some embodiments, the multi-functional polypeptide includes two or more of the IFNα2b or functional fragments thereof. In a preferred embodiment, the multi-functional polypeptide includes a single copy of the IFNα2b or functional fragment thereof.
In some embodiments, the multi-functional polypeptide includes an Fc fragment. In some embodiments, the IFNα2b or a functional fragment thereof is disposed on the C-terminal side of the Fc fragment. In some embodiments, the antibody or antigen-binding fragment thereof is disposed on the N-terminal side of the Fc fragment.
In some embodiments, Fc fragment comprises knob-in-hole substitutions as compared to the corresponding wild-type Fc fragment. Example substitutions to implement the knob-in-hole include S354C: T366W (EU numbering) in the CH3 to form a knob and Y349C: T366S: Y407V (EU numbering) to make a hole.
In some embodiments, the antibody or antigen-binding fragment thereof has specificity to a tumor associated antigen or immune checkpoint protein. Non-limiting examples of tumor associated antigen include EGFR, Her2, EpCAM, CD20, CD30, CD33, CD47, CD52, CD133, CD73, CEA, gpA33, Mucins, TAG-72, CIX, PSMA, folate-binding protein, GD2, GD3, GM2, VEGF, VEGFR, Integrin, aVb3, a5b1, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP, Tenascin, and Claudin 18.2.
Non-limiting examples immune checkpoint protein include PD-1, PD-L1, CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX-40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM, BTLA, KIR, and CD47. In a
particular embodiment, the immune checkpoint protein is PD-L1.
PD-L1/PD-1 antibodies
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1) , activates downstream signaling pathways and inhibits T cell activation. Moreover, abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape. Immunotherapies that target PD-1/PD-L1 signaling pathway have shown unprecedented success in a wide variety of human cancers.
As used herein, the term “PD-1/PD-L1 antibody” refers to any antibody that blocks the binding of PD-L1 expressed on a cancer cell to PD-1 expressed on an immune cell (T cell, B cell or NKT cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune-cell expressed PD-1. Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279 and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, CD274 and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, and CD273 for PD-L2. PD-1/PD-L1 antibody that can be used in the present application includes but is not limited to a monoclonal antibody (mAb) , or antigen binding fragment thereof, which specifically binds to PD-1 or PD-L1, and preferably specifically binds to human PD-1 or human PD-L1. In some embodiments, the antibody includes but is not limited to a polyclonal antibody, a bispecific antibody, and a multispecific antibody. In some embodiments, the antigen binding fragment includes but is not limited to Fab, scFv, diabody, triabody, minibody, VHH, sdAb and nanobody.
Any suitable “PD-1 antibody” known in the art can be used in the present application. In some embodiments, the PD-1 antibody that can be used in the present application includes but is not limited to polyclonal antibody, monoclonal antibody, Fab, scFv, diabody, triabody, minibody, VHH, sdAb and nanobody. Exemplary PD-1 antibodies include but are not limited to pidilizumab, cemiplimab, sintilimab, cetrelimab, spartalizumab, camrelizumab, tislelizumab, balstilimab, toripalimab, dostarlimab, ABBV-181, penpulimab, pembrolizumab, genolimzumab, retifanlimab, sasanlimab, AMP-224, AB122, F-520, MEDI-3387, MEDI-5771, MEDI-0680, SG-001, nivolumab, BCD-100, BAT-1306, BI-754091, CBT-501, GLS-010, LZM-009, Sym-021, CS-1003, HLX-10, AK-103, AM-0001, ENUM-244C8, ENUM-388D4, JTX-4014, RXI-762, STI-A1110, HLX-20, SSI-361, APL-501, TJ0141H, SNA-01, and an antigen binding fragment thereof.
Any suitable “PD-L1 antibody” known in the art can be used in the present application. In some embodiments, the PD-L1 antibody that can be used in the present application includes but is not limited to polyclonal antibody, monoclonal antibody, Fab, scFv, diabody, triabody, minibody, VHH, sdAb and nanobody. Exemplary anti-PD-L1 antibodies include but are not limited to manelimab, atezolizumab, avelumab, cosibelimab, durvalumab, envafolimab, socazolimab, BGB-A333, CK-301, CS-1001, FAZ-053, APL-502, MDX-1105, IMC-001, KD-005, Gensci-047, LY-3300054, SHR-1316, MSB-2311, AVA-004, CBT-502, JS-003, B12, KY-1003, and an antigen binding fragment thereof.
In some embodiments, the “PD-L1” antibody used in the present application is a single domain antibody (sdAb, also referred as “nanobody” herein) . In some embodiments, the sdAb has binding specificity to the human PD-L1 protein and comprises a complementarity determining region 1 (CDR1) , a CDR2 and a CDR3. In some embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6. In some embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6, and the CDR1, CDR2 and CDR3 are according to Kabat numbering scheme. In some embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6, and the CDR1, CDR2 and CDR3 are according to IMGT numbering scheme. In some embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6, and the CDR1, CDR2 and CDR3 are according to Chothia numbering scheme.
In some embodiments of the PD-L1 antibody of the present application, the PD-L1 antibody comprises: (1) a CDR1 comprising the amino acid sequence of FRHYVMG (SEQ ID NO: 3) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 3, (2) a CDR2 comprising the amino acid sequence of AISWSGSGSYYADSVKG (SEQ ID NO: 4) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 4, and (3) a CDR3 comprising the amino acid sequence of DMTTRMSQASREYDY (SEQ ID NO: 5) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 5.
In some embodiments of the PD-L1 antibody of the present application, the PD-L1 antibody comprises the amino acid sequence as set forth in SEQ ID NO: 6, or an amino acid sequence having at least 80%, 85%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity with SEQ ID NO: 6.
In some embodiments, the sdAb has binding specificity to the human PD-L1 protein and comprises a complementarity determining region 1 (CDR1) , a CDR2 and a CDR3. In some
embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 49. In some embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 49, and the CDR1, CDR2 and CDR3 are according to Kabat numbering scheme. In some embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 49, and the CDR1, CDR2 and CDR3 are according to IMGT numbering scheme. In some embodiments, the sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 49, and the CDR1, CDR2 and CDR3 are according to Chothia numbering scheme.
In some embodiments of the PD-L1 antibody of the present application, the PD-L1 antibody comprises: (1) a CDR1 comprising the amino acid sequence of SGTQFSDSKID (SEQ ID NO: 50) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 50, (2) a CDR2 comprising the amino acid sequence of GIFQTGSTIYEDSVKG (SEQ ID NO: 51) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 51, and (3) a CDR3 comprising the amino acid sequence of IGRGTLA (SEQ ID NO: 52) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 52.
In some embodiments of the PD-L1 antibody of the present application, the PD-L1 antibody comprises the amino acid sequence as set forth in SEQ ID NO: 49, or an amino acid sequence having at least 80%, 85%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity with SEQ ID NO: 49.
Modification with Chemical Moiety
In some embodiments of the polypeptide of the present application, the IFNα2b or the functional fragment is modified by a chemical moiety. In some embodiments, the chemical moiety comprises a structure of formula (I) : R1-R2-R3-R4 (I) , wherein R1 is
which is optionally further substituted with 1, 2 or 3 R*group (s) ; L1 is selected from CH or N; R1a is absent, or is selected from the group consisting of - (CH2) 0-3-C (O) -, - (CH2) 0-3-OC (O) -, and - (CH2) 0-3-NHC (O) -; each R1b is independently absent, or is independently selected from the group consisting of -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-, -NH-C1-6 alkyl-, -O-C1-6 alkyl-, -C (O) -C1-6 alkyl-, -OC (O) -C1-6 alkyl-, -C (O) O-C1-6 alkyl-and -C (O) NH-C1-6 alkyl-; each R1c is independently selected from the group consisting of H, C1-6 alkyl, and C1-6 haloalkyl; m is an
integer in a range of 1 to 30000; R*is selected from H, halogen, C1-6 alkyl or C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, or C2-6 alkynyl; R2 is a linker which is cleavable under tumor environment; R3 is X is selected from -NH-or -O-; Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, -C (O) -C (O) -or -NHC (O) -; each Rx and Ry is independently selected from H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl; n is 0, 1, 2, 3, 4, or 5; R4 is Ra and Rb are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxyl; R4a is absent, or is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-, (C1-6 alkylene-O) p- (CH2) 1-12, - (CH2) 1-12-C3-8 cycloalkylene-, - (CH2) 1-12-C3-8 cycloalkylene- (CH2) 1-12, - (CH2) 1-12-C6-10 arylene-, and - (CH2) 1-12-C6-10 arylene- (CH2) 1-12; R4a is optionally further substituted with 1, 2, 3, 4 or 5 R#group (s) ; R4b is selected from the group consisting of -NH-, -O-, -C (O) -, -C (O) O-, -OC (O) -, -C (O) -C (O) -, -C (O) NH-or -NHC (O) -, as long as the chemistry permits; R#is selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl or C2-6 alkynyl; p is 1, 2, 3, 4 or 5; wherein R3 links to R2 via the X of R3, and links to R4 via the Y of R3.
R1
In a specific embodiment, R1 is such as which is optionally substituted; in another specific embodiment, R1 is in another specific embodiment, R1 isin another specific embodiment, R1 is in another specific embodiment, R1 is PEGm, which is a linear polyethylene glycol having a molecular weight of about 20000.
In a specific embodiment, R1 is not further substituted with an R*group; in a specific embodiment, R1 is further substituted with 1 R*group; in a specific embodiment, R1 is further substituted with 2 R*groups; in a specific embodiment, R1 is further substituted with 3 R*
groups.
L1
In a specific embodiment, L1 is CH; in another specific embodiment, L1 is N.
R1a
In a specific embodiment, R1a is absent; in another specific embodiment, R1a is - (CH2) 0-3-C (O) -, such as -C (O) -; in another specific embodiment, R1a is - (CH2) 0-3-OC (O) -, such as -OC (O) -; in another specific embodiment, R1a is - (CH2) 0-3-NHC (O) -, such as -NHC (O) -; as long as the chemistry permits.
R1b
In a specific embodiment, R1b is absent; in another specific embodiment, R1b is NH-; in another specific embodiment, R1b is -O-; in another specific embodiment, R1b is -C (O) -; in another specific embodiment, R1b is -OC (O) -; in another specific embodiment, R1b is -C (O) O-; in another specific embodiment, R1b is -C (O) NH-; in another specific embodiment, R1b is -NH-C1-6 alkyl-, preferably -NH-C1-4 alkyl-; in another specific embodiment, R1b is -O-C1-6 alkyl-, preferably -O-C1-4 alkyl-; in another specific embodiment, R1b is -C (O) -C1-6 alkyl-, preferably -C (O) -C1-4 alkyl-; in another specific embodiment, R1b is -OC (O) -C1-6 alkyl-, preferably -OC (O) -C1-4 alkyl-; in another specific embodiment, R1b is -C (O) O-C1-6 alkyl-, preferably -C (O) O-C1-4 alkyl-; in another specific embodiment, R1b is -C (O) NH-C1-6 alkyl-, preferably -C (O) NH-C1-4 alkyl-.
R1c
In a specific embodiment, R1c is H; in another specific embodiment, R1c is C1-6 alkyl, preferably C1-4 alkyl; in another specific embodiment, R1c is C1-6 haloalkyl, preferably C1-4 haloalkyl.
m
In a specific embodiment, m is an integer in a range of 1 to 30000; in another specific embodiment, m is independently an integer in a range of 1 to 5000; in another specific embodiment, m is independently an integer in a range of 1 to 3000; in another specific embodiment, m is independently an integer in a range of 1 to 1000; in another specific
embodiment, m is independently an integer in a range of 100 to 500; in another specific embodiment, m is independently an integer in a range of 400 to 500.
R*
In a specific embodiment, R*is H; in another specific embodiment, R*is halogen; in another specific embodiment, R*is C1-6 alkyl, preferably C1-4 alkyl; in another specific embodiment, R*is C1-6 haloalkyl, preferably C1-4 haloalkyl; in another specific embodiment, R*is C1-6 alkoxy, preferably C1-4 alkoxy; in another specific embodiment, R*is C2-6 alkenyl; in another specific embodiment, R*is C2-6 alkynyl.
R2
In a specific embodiment, R2 is a linker which is cleavable under tumor environment; in another specific embodiment, R2 is a cleavable linker, and the cleavable linker is selected from the group consisting of matrix metalloprotease (MMP) cleavable linker, a disintegrin and metalloprotease domain-containing (ADAM) metalloprotease cleavable linker, a prostate specific antigen (PSA) protease cleavable linker, a urokinase-type plasminogen activator (uPA) protease cleavable linker, a membrane type serine protease 1 (MT-SP1) protease cleavable linker, a matriptase protease cleavable linker (ST14) or a legumain protease cleavable linker.
In a specific embodiment, R2 is a matrix metalloprotease (MMP) cleavable linker, and the matrix metalloprotease (MMP) cleavable linker comprises an amino acid sequence of AHGL (SEQ ID NO: 54) or PRQV (SEQ ID NO: 61) .
In a specific embodiment, R2 is a prostate specific antigen (PSA) protease cleavable linker, and the prostate specific antigen (PSA) protease cleavable linker comprises an amino acid sequence of HSSKLQ (SEQ ID NO: 15) .
In a specific embodiment, R2 is urokinase-type plasminogen activator (uPA) protease cleavable linker, and the urokinase-type plasminogen activator (uPA) protease cleavable linker comprises an amino acid sequence of SGRSA (SEQ ID NO: 11) .
In a specific embodiment, R2 is a legumain protease cleavable linker, and the legumain protease cleavable linker comprises an amino acid sequence of AAN.
R3
In a specific embodiment, R3 is in another specific embodiment, R3 is
X
In a specific embodiment, X is -NH-; in another specific embodiment, X is -O-.
Y
In a specific embodiment, Y is -NH-; in another specific embodiment, Y is -O-; in another specific embodiment, Y is -C (O) -; in another specific embodiment, Y is -OC (O) -; in another specific embodiment, Y is -C (O) -C (O) -; in another specific embodiment, Y is -NHC (O) -; as long as the chemistry permits.
Rx
In a specific embodiment, Rx is H; in another specific embodiment, Rx is halogen; in another specific embodiment, Rx is C1-6 alkyl, preferably C1-4 alkyl; in another specific embodiment, Rx is C1-6 alkoxy, preferably C1-4 alkoxy; in another specific embodiment, Rx is C1-6 haloalkyl, preferably C1-4 haloalkyl; in another specific embodiment, Rx is C2-6 alkenyl; in another specific embodiment, Rx is C2-6 alkynyl.
Ry
In a specific embodiment, Ry is H; in another specific embodiment, Ry is halogen; in another specific embodiment, Ry is C1-6 alkyl, preferably C1-4 alkyl; in another specific embodiment, Ry is C1-6 alkoxy, preferably C1-4 alkoxy; in another specific embodiment, Ry is C1-6 haloalkyl, preferably C1-4 haloalkyl; in another specific embodiment, Ry is C2-6 alkenyl; in another specific embodiment, Ry is C2-6 alkynyl.
n
In a specific embodiment, n is 0; in another specific embodiment, n is 1; in another specific embodiment, n is 2; in another specific embodiment, n is 3; in another specific embodiment, n is 4; in another specific embodiment, n is 5.
R4
In a specific embodiment, R4 is
Ra
In a specific embodiment, Ra is H; in another specific embodiment, Ra is C1-6 alkyl, preferably C1-4 alkyl; in another specific embodiment, Ra is C1-6 haloalkyl, preferably C1-4 haloalkyl; in another specific embodiment, Ra is C1-6 alkoxyl, preferably C1-4 alkoxyl.
Rb
In a specific embodiment, Rb is H; in another specific embodiment, Rb is C1-6 alkyl, preferably C1-4 alkyl; in another specific embodiment, Rb is C1-6 haloalkyl, preferably C1-4 haloalkyl; in another specific embodiment, Rb is C1-6 alkoxyl, preferably C1-4 alkoxyl.
R4a
In a specific embodiment, R4a is absent; in another specific embodiment, R4a is - (CH2) 1-12-; in another specific embodiment, R4a is - (CH2) 1-12-O-; in another specific embodiment, R4a is -O- (CH2) 1-12-; in another specific embodiment, R4a is -O- (CH2) 1-12-O-; in another specific embodiment, R4a is - (CH2) 1-12-O- (CH2) 1-12-; in another specific embodiment, R4a is (C1-6 alkylene-O) p- (CH2) 1-12; in another specific embodiment, R4a is - (CH2) 1-12-C3-8 cycloalkylene-; in another specific embodiment, R4a is - (CH2) 1-12-C3-8 cycloalkylene- (CH2) 1-12; in another specific embodiment, R4a is - (CH2) 1-12-C6-10 arylene-; in another specific embodiment, R4a is - (CH2) 1-12-C6-10 arylene- (CH2) 1-12.
In a specific embodiment, R4a is not further substituted with an R#group; in a specific embodiment, R4a is further substituted with 1 R#group; in a specific embodiment, R4a is further substituted with 2 R#groups; in a specific embodiment, R4a is further substituted with 3 R#groups; in a specific embodiment, R4a is further substituted with 4 R#groups; in a specific embodiment, R4a is further substituted with 5 R#groups.
R4b
In a specific embodiment, R4a is -NH-; in another specific embodiment, R4a is -O-; in
another specific embodiment, R4a is -C (O) -; in another specific embodiment, R4a is -C (O) O-; in another specific embodiment, R4a is -OC (O) -; in another specific embodiment, R4a is -C (O) -C (O) -; in another specific embodiment, R4a is -C (O) NH-; in another specific embodiment, R4a is -NHC (O) -; as long as the chemistry permits.
R#
In a specific embodiment, R#is H; in another specific embodiment, R#is halogen; in another specific embodiment, R#is C1-6 alkyl, preferably C1-4 alkyl; in another specific embodiment, R#is C1-6 haloalkyl, preferably C1-4 haloalkyl; in another specific embodiment, R#is C1-6 alkoxy, preferably C1-4 alkoxy; in another specific embodiment, R#is C2-6 alkenyl; in another specific embodiment, R#is C2-6 alkynyl.
p
In a specific embodiment, p is 1; in another specific embodiment, p is 2; in another specific embodiment, p is 3; in another specific embodiment, p is 4; in another specific embodiment, p is 5.
Definitions of specific functional groups and chemical terms are described in more detail below.
When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, “C1-6 alkyl” is intended to include C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5 and C5-6 alkyl.
“C1-6 alkyl” refers to a radical of a straight or branched, saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C1-4 alkyl is alternative. Examples of C1-6 alkyl include methyl (C1) , ethyl (C2) , n-propyl (C3) , iso-propyl (C3) , n-butyl (C4) , tert-butyl (C4) , sec-butyl (C4) , iso-butyl (C4) , n-pentyl (C5) , 3-pentyl (C5) , pentyl (C5) , neopentyl (C5) , 3-methyl-2-butyl (C5) , tert-pentyl (C5) and n-hexyl (C6) . The term “C1-6 alkyl” also includes heteroalkyl, wherein one or more (e.g., 1, 2, 3 or 4) carbon atoms are subsituted with heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) . Alkyl groups can be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents or 1 substituent. Conventional abbreviations of alkyl include Me (-CH3) , Et (-CH2CH3) , iPr (-CH (CH3) 2) , nPr (-CH2CH2CH3) , n-Bu (-CH2CH2CH2CH3) or i-Bu (-CH2CH (CH3) 2) .
“C2-6 alkenyl” refers to a radical of a straight or branched hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C2-4 alkenyl is alternative. Examples of C2-6 alkenyl include vinyl (C2) , 1-propenyl (C3) , 2-propenyl (C3) , 1-butenyl (C4) , 2-butenyl (C4) , butadienyl (C4) , pentenyl (C5) , pentadienyl (C5) , hexenyl (C6) , etc. The term “C2-6 alkenyl” also includes heteroalkenyl, wherein one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) . The alkenyl groups can be optionally substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents or 1 substituent.
“C2-6 alkynyl” refers to a radical of a straight or branched hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond and optionally one or more carbon-carbon double bonds. In some embodiments, C2-4 alkynyl is alternative. Examples of C2-6 alkynyl include, but are not limited to, ethynyl (C2) , 1-propynyl (C3) , 2-propynyl (C3) , 1-butynyl (C4) , 2-butynyl (C4) , pentynyl (C5) , hexynyl (C6) , etc. The term “C2-6 alkynyl” also includes heteroalkynyl, wherein one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) . The alkynyl groups can be substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents or 1 substituent.
“C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene” refers to a divalent group of the “C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl” as defined above.
“C1-6 alkylene” refers to a divalent group formed by removing another hydrogen of the C1-6 alkyl, and can be substituted or unsubstituted. In some embodiments, C1-4 alkylene is yet alternative. The unsubstituted alkylene groups include, but are not limited to, methylene (-CH2-) , ethylene (-CH2CH2-) , propylene (-CH2CH2CH2-) , butylene (-CH2CH2CH2CH2-) , pentylene (-CH2CH2CH2CH2CH2-) , hexylene (-CH2CH2CH2CH2CH2CH2-) , etc. Examples of substituted alkylene groups, such as those substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted methylene (-CH (CH3) -, -C (CH3) 2-) , substituted ethylene (-CH (CH3) CH2-, -CH2CH (CH3) -, -C (CH3) 2CH2-, -CH2C (CH3) 2-) , substituted propylene (-CH (CH3) CH2CH2-, -CH2CH (CH3) CH2-, -CH2CH2CH (CH3) -, -C (CH3) 2CH2CH2-, -CH2C (C H3) 2CH2-, -CH2CH2C (CH3) 2-) , etc.
“C2-6 alkenylene” refers to a C2-6 alkenyl group wherein another hydrogen is removed to provide a divalent radical of alkenylene, and which may be substituted or unsubstituted. In
some embodiments, C2-4 alkenylene is yet alternative. Exemplary unsubstituted alkenylene groups include, but are not limited to, ethenylene (-CH=CH-) and propenylene (e.g., -CH=CHCH2-, -CH2-CH=CH-) . Exemplary substituted alkenylene groups, e.g., substituted with one or more alkyl (methyl) groups, include but are not limited to, substituted ethylene (-C (CH3) =CH-, -CH=C (CH3) -) , substituted propylene (e.g., -C (CH3) =CHCH2-, -CH=C (CH3) CH2-, -CH=CHCH (CH3) -, -CH=CHC (CH3) 2-, -CH (CH3) -CH=CH-, -C (CH3) 2-CH=CH-, -CH2-C (CH3) =CH-, -CH2-CH=C (CH3) -) , and the like.
“C2-6 alkynylene” refers to a C2-6 alkynyl group wherein another hydrogen is removed to provide a divalent radical of alkynylene, and which may be substituted or unsubstituted. In some embodiments, C2-4 alkynylene is yet alternative. Exemplary alkynylene groups include, but are not limited to, ethynylene (-C≡C-) , substituted or unsubstituted propynylene (-C≡CCH2-) , and the like.
“Halo” or “halogen” refers to fluorine (F) , chlorine (Cl) , bromine (Br) and iodine (I) . Thus, “C1-6 haloalkyl” refers to the above “C1-6 alkyl” , which is substituted by one or more halogen. In some embodiments, C1-4 haloalkyl is yet alternative, and still alternatively C1-2 haloalkyl. Exemplary haloalkyl groups include, but are not limited to, -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2, 2, 2-trifluoro-1, 1-dimethyl-ethyl, and the like. The haloalkyl can be substituted at any available point of attachment, for example, with 1 to 5 substituents, 1 to 3 substituents or 1 substituent.
“C3-8 cycloalkyl” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 8 ring carbon atoms and zero heteroatoms. In some embodiments, C3-6 cycloalkyl is yet alternative, and still alternatively C5-6 cycloalkyl. The cycloalkyl also includes a ring system in which the cycloalkyl described herein is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the cycloalkyl ring, and in such case, the number of carbon atoms continues to represent the number of carbon atoms in the cycloalkyl system. Exemplary cycloalkyl groups include, but are not limited to, cyclopropyl (C3) , cyclopropenyl (C3) , cyclobutyl (C4) , cyclobutenyl (C4) , cyclopentyl (C5) , cyclopentenyl (C5) , cyclohexyl (C6) , cyclohexenyl (C6) , cyclohexadienyl (C6) , cycloheptyl (C7) , cycloheptenyl (C7) , cycloheptadienyl (C7) , cycloheptatrienyl (C7) , etc. The cycloalkyl can be substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents or 1 substituent.
“C3-8 cycloalkylene” refers to a C3-8 cycloalkyl wherein another hydrogen is removed to provide a divalent radical of cycloalkylene, and which may be substituted or unsubstituted. In some embodiments, C3-7 alkenylene is yet alternative.
“C6-10 aryl” refers to a radical of monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring system having 6-10 ring carbon atoms and zero heteroatoms (e.g., having 6 or 10 shared π electrons in a cyclic array) . In some embodiments, the aryl group has six ring carbon atoms ( “C6 aryl” ; for example, phenyl) . In some embodiments, the aryl group has ten ring carbon atoms ( “C10 aryl” ; for example, naphthyl, e.g., 1-naphthyl and 2-naphthyl) . The aryl group also includes a ring system in which the aryl ring described above is fused with one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the aryl ring system. The aryl can be substituted with one or more substituents, for example, with 1 to 5 substituents, 1 to 3 substituents or 1 substituent.
“C6-10 arylene” refers to a C6-10 aryl wherein another hydrogen is removed to provide a divalent radical of arylene, and which may be substituted or unsubstituted. In some embodiments, phenylene is yet alternative.
“Oxo” represents =O.
Alkyl, alkenyl, alkynyl, cycloalkyl, and aryl as defined herein are optionally substituted groups. Exemplary substituents on carbon atoms include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORaa, -ON (Rbb) 2, -N (Rbb) 2, -N (Rbb) 3
+X-, -N (ORcc) Rbb, -SH, -SRaa, -SSRcc, -C (=O) Raa, -CO2H, -CHO, -C (ORcc) 2, -CO2Raa, -OC (=O) Raa, -OC O2Raa, -C (=O) N (Rbb) 2, -OC (=O) N (Rbb) 2, -NRbbC (=O) Raa, -NRbbCO2Raa, -NRbbC (=O) N (Rbb) 2, -C (=NRbb) Raa, -C (=NRbb) ORaa, -OC (=NRbb) Raa, -OC (=NRbb) ORaa, -C (=NRbb) N (Rbb) 2, -OC (=NRbb) N (Rbb) 2, -NRbbC (=NRbb) N (Rbb) 2, -C (=O) NRbbSO2Raa, -NRbbSO2Raa, -SO2N (Rbb) 2, -SO2 Raa, -SO2ORaa, -OSO2Raa, -S (=O) Raa, -OS (=O) Raa, -Si (Raa) 3, -OSi (Raa) 3, -C (=S) N (Rbb) 2, -C (=O) SRaa, -C (=S) SRaa, -SC (=S) SRaa, -SC (=O) SRaa, -OC (=O) SRaa, -SC (=O) ORaa, -SC (=O) Raa, -P (=O) 2Raa, -OP (=O) 2Raa, -P (=O) (Raa) 2, -OP (=O) (Raa) 2, -OP (=O) (ORcc) 2, -P (=O) 2N (Rbb) 2, -OP (=O) 2N (Rbb) 2, -P (=O) (NRbb) 2, -OP (=O) (NRbb) 2, -NRbbP (=O) (ORcc) 2, -NRbbP (=O) (NRbb) 2, -P (Rcc) 2, -P (Rcc) 3, -OP (Rcc) 2, -OP (Rcc) 3, -B (Raa) 2, -B (ORcc) 2, -BRaa (ORcc) , alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2,
3, 4 or 5 Rdd groups; or two geminal hydrogen on a carbon atom are replaced with =O, =S, =NN (Rbb) 2, =NNRbbC (=O) Raa, =NNRbbC (=O) ORaa, =NNRbbS (=O) 2Raa, =NRbb or =NORcc groups; each of the Raa is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two of the Raa groups are combined to form a heterocyclyl or heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2, 3, 4 or 5 Rdd groups; each of the Rbb is independently selected from hydrogen, -OH, -ORaa, -N (Rcc) 2, -CN, -C (=O) Raa, -C (=O) N (Rcc) 2, -CO2Raa, -SO2Raa, -C (=NRc c) ORaa, -C (=NRcc) N (Rcc) 2, -SO2N (Rcc) 2, -SO2Rcc, -SO2ORcc, -SORaa, -C (=S) N (Rcc) 2, -C (=O) SRcc, -C (=S) SRcc, -P (=O) 2Raa, -P (=O) (Raa) 2, -P (=O) 2N (Rcc) 2, -P (=O) (NRcc) 2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two Rbb groups are combined to form a heterocyclyl or a heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2, 3, 4 or 5 Rdd groups; each of the Rcc is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two Rcc groups are combined to form a heterocyclyl or a heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2, 3, 4 or 5 Rdd groups; each of the Rdd is independently selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORee, -ON (Rff) 2, -N (Rff) 2, -N (Rff) 3
+X-, -N (OR ee) Rff, -SH, -SRee, -SSRee, -C (=O) Ree, -CO2H, -CO2Ree, -OC (=O) Ree, -OCO2Ree, -C (=O) N (Rff) 2, -OC (=O) N (Rff) 2, -NRffC (=O) Ree, -NRffCO2Ree, -NRffC (=O) N (Rff) 2, -C (=NRff) ORee, -OC (=NRff) Ree, -OC (=NRff) ORee, -C (=NRff) N (Rff) 2, -OC (=NRff) N (Rff) 2, -NRffC (=NRff) N (Rff) 2, -NRf fSO2Ree, -SO2N (Rff) 2, -SO2Ree, -SO2ORee, -OSO2Ree, -S (=O) Ree, -Si (Ree) 3, -OSi (Ree) 3, -C (=S) N (Rff) 2, -C (=O) SRee, -C (=S) SRee, -SC (=S) SRee, -P (=O) 2Ree, -P (=O) (Ree) 2, -OP (=O) (Ree) 2, -OP (=O) (ORee) 2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2, 3, 4 or 5 Rgg groups, or two geminal Rdd substituents can be combined to form=O or =S; each of the Ree is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2, 3, 4 or 5 Rgg groups;
each of the Rff is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl,
cycloalkyl, heterocyclyl, aryl and heteroaryl, or two Rff groups are combined to form a heterocyclyl or a heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2, 3, 4 or 5 Rgg groups; each of the Rgg is independently selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC1-6 alkyl, -ON (C1-6 alkyl) 2, -N (C1-6 alkyl) 2, -N (C1-6 alkyl) 3
+X-, -NH (C1-6 alkyl) 2
+X-, -NH2 (C1-6 alkyl) +X-, -NH3
+X-, -N (OC1-6 alkyl) (C1-6 alkyl) , -N (OH) (C1-6 alkyl) , -NH (OH) , -SH, -SC1-6 alkyl, -SS (C1-6 alkyl) , -C (=O) (C1-6 alkyl) , -CO2H, -CO2 (C1-6 alkyl) , -OC (=O) (C1-6 alkyl) , -OCO2 (C1-6 alkyl) , -C (=O) NH2, -C (=O) N (C1-6 alkyl) 2, -OC (=O) NH (C1-6 alkyl) , -NHC (=O) (C1-6 alkyl) , -N (C1-6 alkyl) C (=O) (C1-6 alkyl) , -NHCO2 (C1-6 alkyl) , -NHC (=O) N (C1-6 alkyl) 2, -NHC (=O) NH (C1-6 alkyl) , -NHC (=O) NH2, -C (=NH) O (C1-6 alkyl) , -OC (=NH) (C1-6 alkyl) , -OC (=NH) OC1-6 alkyl, -C (=NH) N (C1-6 alkyl) 2, -C (=NH) NH (C1-6 alkyl) , -C (=NH) NH2, -OC (=NH) N (C1-6 alkyl) 2, -OC (NH) NH (C1-6 alkyl) , -OC (NH) NH2, -NHC (NH) N (C1-6 alkyl) 2, -NHC (=NH) NH2, -NHSO2 (C1-6 alkyl) , -SO2N (C1-6 alkyl) 2, -SO2NH (C1-6 alkyl) , -SO2NH2, -SO2C1-6 alkyl, -SO2OC1-6 alkyl, -OSO2C1-6 alkyl, -SOC1-6 alkyl, -Si (C1-6 alkyl) 3, -OSi (C1-6 alkyl) 3, -C (=S) N (C1-6 alkyl) 2, C (=S) NH (C1-6 alkyl) , C (=S) NH2, -C (=O) S (C1-6 alkyl) , -C (=S) SC1-6 alkyl, -SC (=S) SC1-6 alkyl, -P (=O) 2 (C1-6 alkyl) , -P (=O) (C1-6 alkyl) 2, -OP (=O) (C1-6 alkyl) 2, -OP (=O) (OC1-6 alkyl) 2, C1-6 alkyl, C1-6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C6-C10 aryl, C3-C7 heterocyclyl, C5-C10 heteroaryl; or two geminal Rgg substituents may combine to form =O or =S;wherein X-is a counter-ion.
Exemplary substituents on nitrogen atoms include, but are not limited to, hydrogen, -OH, -ORaa, -N (Rcc) 2, -CN, -C (=O) Raa, -C (=O) N (Rcc) 2, -CO2Raa, -SO2Raa, -C (=NRb
b) Raa, -C (=NRcc) ORaa, -C (=NRcc) N (Rcc) 2, -SO2N (Rcc) 2, -SO2Rcc, -SO2ORcc, -SORaa, -C (=S) N (Rcc) 2, -C (=O) SRcc, -C (=S) SRcc, -P (=O) 2Raa, -P (=O) (Raa) 2, -P (=O) 2N (Rcc) 2, -P (=O) (NRcc) 2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two Rcc groups attached to a nitrogen atom combine to form a heterocyclyl or a heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2, 3, 4 or 5 Rdd groups, and wherein Raa, Rbb, Rcc and Rdd are as described herein.
In some embodiments of the polypeptide of the present application, the chemical moiety comprises a structure of formula (I) : R1-R2-R3-R4 (I) , wherein R1 is
which is optionally further substituted with 1, 2 or 3 R*group (s) ; L1 is selected from CH or N; R1a is absent, or is selected from the group consisting of -C (O) -, -OC (O) -, and -NHC (O) -; each R1b is independently absent, or is independently selected from the group consisting of -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-, -NH-C1-4 alkyl-, -O-C1-4 alkyl-, -C (O) -C1-4 alkyl-, -OC (O) -C1-4 alkyl-, -C (O) O-C1-4 alkyl-and -C (O) NH-C1-4 alkyl-; each R1c is independently selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl; each m is independently an integer in a range of 1 to 5000; R*is selected from H, halogen, C1-6 alkyl or C1-6 haloalkyl; alternatively, R1 is which is optionally further substituted with 1, 2 or 3 R*group (s) ; R1a is absent, or is -C (O) -; R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl; m is an integer in a range of 1 to 3000; R*is selected from H, halogen or C1-4 alkyl; still alternatively, R1 is R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500; yet alternatively, R1 is a linear polyethylene glycol having a molecular weight of about 20000.
In some embodiments of the polypeptide of the present application, the chemical moiety comprises a structure of formula (I) : R1-R2-R3-R4 (I) , wherein R2 is selected from the group consisting of matrix metalloprotease (MMP) cleavable linker, a disintegrin and metalloprotease domain-containing (ADAM) metalloprotease cleavable linker, a prostate specific antigen (PSA) protease cleavable linker, a urokinase-type plasminogen activator (uPA) protease cleavable linker, a membrane type serine protease 1 (MT-SP1) protease cleavable linker, a matriptase protease cleavable linker (ST14) and a legumain protease cleavable linker. In some embodiments, R2 is a matrix metalloprotease (MMP) cleavable linker. In some embodiments, the MMP cleavable linker comprises an amino acid sequence of any one selected from SEQ ID NOs: 21-35. In some embodiments, R2 is a prostate specific antigen (PSA) protease cleavable linker. In some embodiments, the PSA protease cleavable linker comprises an amino acid sequence of any one selected from SEQ ID NOs: 14-16. In some embodiments, R2 is urokinase-type plasminogen activator (uPA) protease cleavable linker. In some embodiments, the uPA protease cleavable linker comprises an amino acid sequence of any one selected from
SEQ ID NOs: 11-13. In some embodiments, R2 is a legumain protease cleavable linker. In some embodiments, the legumain protease cleavable linker comprises an amino acid sequence of any one selected from SEQ ID NOs: 18-19 or AAN or Cbz-AAN-AMC.
In some embodiments, the chemical moiety comprises a structure of formula (II) : wherein R1, R3 and R4 are as defined above.
In some embodiments of the polypeptide of the present application, the chemical moiety comprises a structure of formula (I) : R1-R2-R3-R4 (I) , wherein R3 is wherein X is selected from -NH-or -O-; Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -; each Rx and Ry is independently selected from H, halogen, C1-4 alkyl or C1-4 haloalkyl; n is 0, 1, 2 or 3; alternatively, R3 is X is selected from NH or O; Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -. In some embodiments, the chemical moiety comprises a structure of formula (III) :
wherein R1, R2 and R4 are as defined above. In some embodiments, the chemical moiety comprises a structure of formula (IV) wherein R1 and R4 are as defined above.
In some embodiments of the polypeptide of the present application, the chemical moiety comprises a structure of formula (I) : R1-R2-R3-R4 (I) , wherein R4 is Ra and Rb are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl and
C1-6 alkoxyl; R4a is absent, or is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-, (C1-6 alkylene-O) p- (CH2) 1-12, - (CH2) 1-12-C3-8 cycloalkylene- and - (CH2) 1-12-C3-8 cycloalkylene- (CH2) 1-12; R4a is optionally further substituted with 1, 2, 3 or 4 R#group (s) ; R4b is -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-or -NHC (O) -; R#is selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl; p is 1, 2, 3 or 4; alternatively, Ra and Rb are each independently selected from the group consisting of H and C1-4 alkyl; R4a is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-and (C1-4 alkylene-O) p- (CH2) 1-12; R4a is optionally further substituted with 1, 2 or 3 R#group (s) ; R4b is -NH-, -O-or -C (O) -; R#is selected from the group consisting of H, halogen, C1-6 alkyl and C1-6 haloalkyl; p is 1, 2 or 3; still alternatively, Ra and Rb are H; R4a is - (CH2) 2-12-; R4b is -NH-; R4a is optionally further substituted with 1 or 2 R#group (s) ; R#is selected from the group consisting of H, halogen and C1-4 alkyl. In some embodiments, the chemical moiety comprises a structure of formula (V) :
wherein R1, R2 and R3 are as defined above.
In some embodiments, the chemical moiety comprises a structure of formula (VI) : wherein the PEGm is R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500. In some embodiments, the PEGm is a linear polyethylene glycol having a molecular weight of about 20000.
In some embodiments of the polypeptide of the present application, the IFNα2b or the functional fragment is modified by the chemical moiety at a residue corresponding to one or more selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1. In some embodiments,
the IFNα2b or the functional fragment is modified by the chemical moiety at the residue corresponding to S152 of SEQ ID NO: 1.
In some embodiments, the IFNα2b or the functional fragment comprises an amino acid substitution at a position corresponding to the position selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1, and the chemical moiety is linked to the IFNα2b or the functional fragment at the substituted amino acid. In some embodiments, the IFNα2b or the functional fragment comprises an amino acid substitution with a cysteine at a position corresponding to the position selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1, and the chemical moiety is linked to the IFNα2b or the functional fragment via the cysteine. In some embodiments, the IFNα2b or the functional fragment comprises an amino acid substitution with a cysteine at a position corresponding to the position of S152 of SEQ ID NO: 1, and the chemical moiety is linked to the IFNα2b or the functional fragment via the cysteine.
In some embodiments, R4 of the chemical moiety is linked to the S atom of the cysteine residue via a maleimide, an acetylene, a vinyl, a mono-substituted butenedioic acid, or a disubstituted maleimide. In some embodiments, R4 of the chemical moiety is linked to the S atom of the cysteine residue via a maleimide.
In some embodiments, the IFNα2b or the functional fragment comprises an amino acid substitution with a cysteine at a position corresponding to S152 of SEQ ID NO: 1, and the chemical moiety is linked to the cysteine through R4 of the chemical moiety via a maleimide, an acetylene, a vinyl, a mono-substituted butenedioic acid, or a disubstituted maleimide. In some embodiments, the IFNα2b or the functional fragment comprises an amino acid substitution with a cysteine at a position corresponding to S152 of SEQ ID NO: 1, and the chemical moiety is linked to the cysteine through R4 of the chemical moiety via a maleimide. In some embodiments, the IFNα2b or the functional fragment comprises an amino acid substitution with a cysteine at a position corresponding to S152 of SEQ ID NO: 1, and a chemical moiety comprising a structure of formula (VI) is linked to the cysteine via the
maleimide: wherein the PEGm is R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500; alternatively, the PEGm is a linear polyethylene glycol having a molecular weight of about 20000.
Bifunctional Immunoconjugates
In another aspect, provided herein is an immunoconjugate comprising the IFNα2b or the functional fragment thereof of the present application, and a biomolecule. In some embodiments, the biomolecule specifically binds to a target. In some embodiments, the biomolecule comprises an antibody or an antigen binding fragment thereof. In some embodiments, the antibody or the antigen binding fragment thereof is selected from the group consisting of a full-length antibody, a Fab, Fab’, a F (ab’) 2, a Fd, a Fd’, a Fv, a scFv, a ds-scFv, a sdAb and a nanobody. In some embodiments, the antibody specifically targets PD-L1 or PD-1. In some embodiments, the biomolecule is a PD-L1/PD-1 antibody as described herein.
In some embodiments of the immunoconjugate of the present application, the biomolecule is a PD-L1 antibody. In some embodiments, the PD-L1 antibody is a sdAb. In some embodiments, the PD-L1 antibody is a sdAb comprising a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6. In some embodiments, the PD-L1 antibody is a sdAb comprising a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 6, and the CDR1, CDR2 and CDR3 are according to Kabat numbering scheme. In some embodiments, the biomolecule is a PD-L1 antibody, and the PD-L1 antibody comprises: (1) a CDR1 comprising an amino acid sequence of FRHYVMG (SEQ ID NO: 3) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 3, (2) a CDR2 comprising an amino acid sequence of AISWSGSGSYYADSVKG (SEQ ID NO: 4) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 4, and (3) a CDR3 comprising an amino acid sequence of DMTTRMSQASREYDY (SEQ ID NO: 5) or an amino acid sequence with one or more substitutions as compared to SEQ ID NO: 5.
In some embodiments, the biomolecule is a PD-L1 antibody, and the PD-L1 antibody comprises an amino acid sequence as set forth in SEQ ID NO: 6, or an amino acid sequence
having at least 80%, 85%, 87%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identity with SEQ ID NO: 6.
In some embodiments, the immunoconjugates comprises any suitable number of the sdAb as described above. In some embodiments, the immunoconjugates comprises 1-4 of the sdAbs as described above. In some embodiments, the immunoconjugates comprises one of the sdAb as described above. In some embodiments, the immunoconjugates comprises two of the sdAbs as described above. In some embodiments, the immunoconjugates comprises four of the sdAbs as described above.
In some embodiments, the immunoconjugate comprises the IFNα2b or the functional fragment thereof as described herein. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate binding affinity of the IFNα2b or the functional fragment thereof with interferon α/β receptor. In some embodiments, the binding affinity of the IFNα2b or the functional fragment thereof with interferon α/β receptor is attenuated to reduce adverse effect of the immunoconjugate after administration to a subject in need thereof. In some embodiments, the IFNα2b or the functional fragment thereof is modified to attenuate activation of Type I Interferon Signaling induced by the IFNα2b or the functional fragment thereof. In some embodiments, the activation of Type I Interferon Signaling is attenuated to reduce adverse effect of the immunoconjugate after administration to a subject in need thereof.
In some embodiments, the adverse effect includes acute toxicity, subacute side effect and chronic side effect. In some embodiments, the acute toxicity includes the flu-like symptoms such as fever, chills, myalgia, headache, and nausea. In some embodiments, the subacute side effect includes but is not limited to hematological side effects such as anemia, decrease in leukocyte and platelet counts and decreased platelet aggregation; hepatic side effects such as raised transaminases and inhibition of cytochrome P450 enzymes; gastro-intestinal side effects such as loss of appetite, nausea, vomiting and diarrhea; psychiatric side effects such as depression, difficulties in cognition and delirium; neurological side effects such as seizures, neuropathies, multiple-sclerosis like disease and mysthenia gravis; renal side effects such as proteinuria; cardiovascular side effects such as arrythmias, ischemic heart disease, cardiomyopathy and retinal abnormalities; pulmonary side effects such as pneumonitis; endocrine side effects such as thyroid disorder, diabetes mellitus, decrement of sex hormone levels and hypopituitarism; dermatological side effects such as alopecia, erythema and induration at injection site, rash, pruritus, vitiligo, lichen planus, psoriasis.
In some embodiments, the side effect includes autoimmune disorders such as thyroid disorder, liver dysfunction, connective tissue diseases, dermatological disorders, hematologic disorders, neurological disorders, pulmonary disorder and metabolic disorder. In some embodiments, the side effect results in disorders including but not limited to subacute lymphocytic thyroiditis, graves’ disease, permanent hypothyroidism, autoimmune hepatitis, primary biliary cirrhosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, leucocytoclastic vasculitis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, inflammatory demyelinating polyneuropathy, multiple sclerosis-like disease, axonal neuropathy and hearing loss, bell’s palsy, mononeuropathy multiplex, myasthenia gravis, abducent nerve paralysis, interstitial pneumonitis and diabetes mellitus.
In some embodiments of the immunoconjugate of the present application, the IFNα2b or the functional fragment thereof is modified to improve the performance of the immunoconjugates after administration to a subject in need thereof. In some embodiments, the performance includes but is not limited to pharmacokinetics (PK) , pharmacodynamics (PD) , efficacy, and safety. In some embodiments, the efficacy includes anti-tumor efficacy. In some embodiments, the anti-tumor efficacy includes but is not limited to inhibiting tumor growth, reducing tumor volume, increasing survival of a subject and inducing protection against tumor recurrence.
In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment thereof modified by an amino acid substitution at one or more residues corresponding to one or more selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1. In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment thereof modified by an amino acid substitution at R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1. In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment thereof modified by an amino acid substitution at S152 of SEQ ID NO: 1. In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment thereof having an amino acid substitution with cysteine at the residue corresponding to S152 of SEQ ID NO: 1.
In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment, and the IFNα2b comprises an amino acid sequence having
at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 1. In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment, and the IFNα2b comprises an amino acid sequence of SEQ ID NO: 1. In some embodiments, the immunoconjugate comprises the IFNα2b, and the IFNα2b comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 2. In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment, and the IFNα2b comprises an amino acid sequence of SEQ ID NO: 2.
In some embodiments, the immunoconjugate of the present application comprises the IFNα2b or the functional fragment, wherein the IFNα2b comprises an amino acid sequence of SEQ ID NO: 2, and is further modified by a chemical moiety at residue C152 of SEQ ID NO: 2, wherein the chemical moiety comprises a structure of formula (VI) : and the PEGm is R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500; alternatively, the PEGm is a linear polyethylene glycol having a molecular weight of about 20000.
In some embodiments, the immunoconjugates comprises any suitable number of the IFNα2b or the functional fragment as described above. In some embodiments, the immunoconjugates comprises 1-4 of the IFNα2b or the functional fragments as described above. In some embodiments, the immunoconjugates comprises one of the IFNα2b or the functional fragment as described above. In some embodiments, the immunoconjugates comprises two of the IFNα2b or the functional fragments as described above. In some embodiments, the immunoconjugates comprises four of the IFNα2b or the functional fragments as described above.
In some embodiments of the immunoconjugate of the present application, the immunoconjugate further comprises an Fc region. The term “Fc-region” as used herein refers to the C-terminal region of an immunoglobulin heavy chain of human origin that contains at
least a part of the hinge region, the CH2 domain and the CH3 domain. Any suitable Fc region known in the art can be used in the immunoconjugate of the present application. In some embodiments, the Fc region can be derived from any suitable IgG isotype, such as IgG1, IgG2, IgG3 or IgG4. In some embodiments, the Fc region is derived from IgG1. In some embodiments, the Fc region further comprises one or more mutation to enhance ADCC function.
In some embodiments, the Fc region comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 7. In some embodiments, the Fc region comprises the amino acid sequence of SEQ ID NO: 7.
In some embodiments of the immunoconjugate of the present application, the IFNα2b or the functional fragment thereof is conjugated to the N terminus of the biomolecule. In some embodiments, the IFNα2b or the functional fragment thereof is conjugated to the C terminus of the biomolecule. In some embodiments, the IFNα2b or the functional fragment thereof is conjugated to the C terminus of the Fc region. In some embodiments of the immunoconjugate, the IFNα2b or the functional fragment thereof is conjugated to the N terminus of the Fc region. In some embodiments, the IFNα2b or the functional fragment thereof is conjugated to the biomolecule through a linker. In some embodiments, the IFNα2b or the functional fragment thereof is conjugated to the Fc region through a linker. Any suitable linker known in the art can be used for the conjugation. In some embodiments, the linker is selected from the group consisting of (GGGGS) n (SEQ ID NO: 53) , (GGGS) n (SEQ ID NO: 54) , (GGS) n, (GmS) n, and (XmS) n, and n is an integer between 1-8.
Exemplary formats of the immunoconjugates of the present application are as illustrated in FIG. 1.
In some embodiments, the immunoconjugate comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 9. In some embodiments, the immunoconjugate comprises the amino acid sequence of SEQ ID NO: 9.
In some embodiments, the immunoconjugate comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 10. In some embodiments, the immunoconjugate comprises the amino acid sequence of SEQ ID NO: 10.
In some embodiments, the immunoconjugate comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 36 and an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 37. In some embodiments, the immunoconjugate comprises the amino acid sequences of SEQ ID NO: 36 and 37.
In some embodiments, the immunoconjugate comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 38 and an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 39. In some embodiments, the immunoconjugate comprises the amino acid sequences of SEQ ID NO: 38 and 39.
In some embodiments, the immunoconjugate comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 40 and an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 41. In some embodiments, the immunoconjugate comprises the amino acid sequences of SEQ ID NO: 40 and 41.
In some embodiments, the immunoconjugate comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 42 and an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 43. In some embodiments, the immunoconjugate comprises the amino acid sequences of SEQ ID NO: 42 and 43.
In some embodiments, the immunoconjugate comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 44 and an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 45. In some embodiments, the immunoconjugate comprises the amino acid sequences of SEQ ID NO: 44 and 45.
In some embodiments, the immunoconjugate comprises an amino acid sequence having
at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 46 and an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%sequence identity to the sequence of SEQ ID NO: 47. In some embodiments, the immunoconjugate comprises the amino acid sequences of SEQ ID NO: 46 and 47.
In another aspect, provided herein is a polynucleotide encoding the polypeptide or the immunoconjugate of the present application. In some embodiments, the polynucleotide comprises the nucleic acid sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%identity with SEQ ID NO: 8. In some embodiments, the polynucleotide comprises the nucleic acid sequence of SEQ ID NO: 8.
In another aspect, provided herein is a vector comprising the polynucleotide as described in the present application. In some embodiments, the term “vector” refers to a DNA molecule that is used to introduce and direct the expression of a specific gene to which it is operably associated in a target cell. In some embodiments, the vector comprises an expression cassette that comprises polynucleotide sequences that encode the polypeptides or immunoconjugates of the present application.
In another aspect, provided herein is a host cell comprising the vector as described in the present application. As used herein, the term “host cell” refers to any kind of cellular system which can be engineered to generate the polypeptides or immunoconjugates of the present application. Host cells suitable for replicating and for supporting expression of the polypeptides or immunoconjugates are well known in the art. Such cells may be transfected or transduced as appropriate with the particular expression vector and large quantities of vector containing cells can be grown for seeding large scale fermenters to obtain sufficient quantities of polypeitide or immunoconjugate for clinical applications. Suitable host cells include prokaryotic microorganisms, such as E. coli, or various eukaryotic cells, such as Chinese hamster ovary cells (CHO) , insect cells, or the like. For example, polypeptides may be produced in bacteria in particular when glycosylation is not needed. After expression, the polypeptide may be isolated from the bacterial cell paste in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for polypeptide-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized, ” resulting in the production of a polypeptide
with a partially or fully human glycosylation pattern. Suitable host cells for the expression of (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates) . Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures can also be utilized as hosts. Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7) ; human embryonic kidney line (293 or 293T cells) , baby hamster kidney cells (BHK) , mouse sertoli cells (TM4 cells, monkey kidney cells (CV1) , African green monkey kidney cells (VERO-76) , human cervical carcinoma cells (HELA) , canine kidney cells (MDCK) , buffalo rat liver cells (BRL 3A) , human lung cells (W138) , human liver cells (Hep G2) , mouse mammary tumor cells (MMT 060562) , TRI cells) , MRC 5 cells, and FS4 cells.
Treatments
In another aspect, provided herein is method for treating a disorder in a subject in need thereof, comprising administrating an effective amount of the polypeptide, the immunoconjugate, or the nucleic acid of the present application to the subject. In some embodiments, the disorder is cancer. In some embodiments, the disorder is a PD-1/PD-L1 antibody treatment resistant cancer.
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
EXAMPLES
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present disclosure, and are not intended to limit the scope of what the inventors regard as their disclosure nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc. ) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
Example 1. Preparation of bifunctional polypeptides and immunoconjugates
Bifunctional molecules that included IFNα2b or a functional fragment and were also capable of targeting PD-L1/PD-1 were designed and expressed in HEK293-based mammalian expression system. The structures of these polypeptides are illustrated in FIG. 1 and their sequences are shown Table 2 below.
Table 2. Amino acid sequences of immunoconjugates
As shown in FIG. 1, various different formats of the bifunctional polypeptides were used. Two of these formats were symmetric, each containing two anti-PD-L1 nanobodies and two IFNα2b molecules. In the first symmetric format (L1IF) on the far left, the two nanobodies were disposed on the N-terminal side of an IgG1 Fc fragment, while the two IFNα2b molecules were on the C-terminal side of the Fc fragment. By contrast, in L1-G4S-IF-Fc (format 1) , the two IFNα2b molecules were between the nanobodies and the Fc fragment.
Five different asymmetric bifunctional polypeptides were made. In L1-Fc (H) +L1-Fc-IF (K) (format 2) , only a single IFNα2b molecule was included, and was fused to the C-terminus of one of the CH3 domains of the Fc fragment. In all of the asymmetric formats, knob-into-hole substitutions were made to reduce mis-pairing. In format 2, the IFNα2b molecule was fused to the CH3 that included the knob. In format 3 (L1-Fc (K) +L1-Fc-IF (H) ) , the IFNα2b molecule is fused to the CH3 that includes the hole.
In format 4 (L1*2-Fc (H) +IF-Fc (K) ) , two anti-PD-L1 nanobodies were connected, in series, to one of the chains (hole) of the Fc fragment while a single IFNα2b was fused to the N-terminus of the other chain (knob) . In format 5 (L1-Fc (H) +IF-G4S-L1-Fc (K) ) , each of the two anti-PD-L1 nanobodies was fused to each of the two Fc chains, while one of the chains further included an IFNα2b molecule at the far N-terminal end. Finally, in format 6 (L1-Fc (H) +L1-G4S-IF-Fc (K) ) , the single IFNα2b molecule was between an N-terminal anti-PD-L1 nanobody and the C-terminal Fc.
In some versions of the bifunctional polypeptides, the IFNα2b molecule was wild-type (WT) . In some of them, the IFNα2b molecule included a S152C substitution (position according to SEQ ID NO: 1) . Bifunctional polypeptides with the S152C substitution is referred to as L1IF M205.
Immunoconjugates, which were based on these bifunctional polypeptides and further included chemical moieties of the present application (L1IF M205 DAR1) were also designed and prepared, as illustrated in FIG. 2A and 2B. The chemical moiety was prepared mainly as described previously (see WO2019091384A1) .
As shown in FIG. 2A, L1IF M205 adopted a symmetric format with bivalent of
L1-Fc-IF arm, in which a substitution at residue S152 (location according to SEQ ID NO: 1) of the IFNa2b component with Cysteine (C) . Then a chemical moiety comprising a maleimide chemical linker, PABC, a legumain cleavable linker and a 20K PEG was linked to the cysteine introduced at residue 152 of IFNa2b in one arm (L1IF M205 DAR1) or both arms of L1IF M205 (L1IF M205 DAR2) . The PEG structure can be cleaved by legumain accumulated in the tumor environment so as to release the active form of the molecule. FIG. 2B shows the SDS-PAGE of L1IF M205 DAR1 and L1IF M205 DAR2 with DTT (left) or without DTT (right) .
Example 2. Binding of the immunoconjugate with PD-L1
Biacore assay was performed to evaluate the binding affinity of the immunoconjugates towards human PD-L1.
Briefly, PD-L1 mAb (SEQ ID NO: 6) , L1IF WT, L1IF M205 and L1IF M205 DAR1 were captured on Protein A chip, respectively, and the flow rate was 10 μL/min. Recombinant human PD-L1 protein served as analyte. The concentration of analyte was 400, 200, 100, 50, 25, 0 nM and the injection rate of analyte was 30 μL/min with 180s association period. The result was analyzed by using 1: 1 Binding fit model. Then KD of L1IF WT, L1IF M205 group and L1IF M205 DAR1 group were normalized to PD-L1 mAb group, respectively, as shown in Table 3 below.
Table 3. Binding affinity of the immunoconjugates of the present application with PD-L1
As shown in Table 3, the binding affinity of L1IF WT, L1IF M205 and L1IF M205 DAR1 with PD-L1 was comparable with that of PD-L1 mAb used in the immunoconjugate, indicating conjugation with the IFNα2b or IFNα2b modified with the chemical moiety of the present application does not affect the binding affinity of the PD-L1 antibody with PD-L1.
Then the binding of the PD-L1 arm of the immunoconjugates was further evaluated by ELISA. Briefly, recombinant human PD-L1 protein was coated in 96-well plate. PD-L1 mAb (SEQ ID NO: 6) , L1IF WT, L1IF M205 and L1IF M205 DAR1 were serially diluted and added to the plate. Goat anti-human IgG Fc HRP was further added as the secondary antibody for
analysis. As shown in FIG. 3A, EC50 of L1IF M205 DAR1 group was 1.292 nM, 3.6 folds change as compared to PD-L1 mAb, while EC50 values of L1IF WT and L1IF M205 groups were comparable with PD-L1 mAb.
In order to mimic the PD-L1 antigen exposure more accurately, the PD-L1 antigen protein was expressed on CHO-K1 cells. Then, the binding activity of the immunoconjugates of the present application to PD-L1 on CHO-K1 cells was detected via FACS. As shown in FIG. 3B, L1IF M205 and L1IF WT exhibited comparable binding capability with PD-L1 mAb, while L1IF M205 DAR1 exhibited slightly reduced binding capability.
Example 3. Activation of PD-L1/PD-1 signaling by the immunoconjugate
To evaluate activation of the PD-L1/PD-1 signaling by the immunoconjugate of the present application, an artificial functional assay system comprising CHO-K1 APCs stably expressing human PD-L1 and OKT3 and Jurkat effector cells stably expressing PD-1, CD3 and NFAT reporter gene was established. In this system, when an antagonist of PD1/PD-L1 signaling is introduced into the system, the inhibition of PD1 to CD3 pathway would be abrogated and NFAT reporter gene induced by CD3 can be detected.
As shown in FIG. 4, after incubation, L1IF WT and L1IF M205 resulted in comparable expression of NFAT report gene with the PD-L1 mAb, while L1IF M205 DAR1 resulted in slightly reduced expression of NFAT reported gene as compared with the PD-L1 mAb.
Example 4. Binding of the immunoconjugate with IFN receptor
Biacore assay was performed to test the binding affinity of the immunoconjugates of the present application with IFN receptor IFNAR1 and IFNAR2. The results are as summarized in Table 4 below.
Table 4. binding affinity of the immunoconjugates with IFNAR1 and IFNAR2
As shown in Table 4, as compared to the control, a commercial available PEG-IFNa2b
without the modification of the present application, L1IF WT exhibited comparable binding affinity with IFNAR1 and IFNAR2; L1IF M205 with S152C substitution in the IFNa2b component of the immunoconjugate exhibited comparable binding affinity with IFNAR1 but attenuated binding with IFNAR2, in which the KD was increased by104 folds; L1IF M205 DAR1 with S152C substitution and an additional chemical moiety attached to the substituted residue in the IFNa2b component of the immunoconjugate exhibited further attenuated binding to both IFNAR1 and IFNAR2 as compared to L1IF M205.
Then the binding capability of the immunoconjugates with IFNAR1 and IFNAR2 was evaluated by ELISA. Briefly, recombinant human IFNAR1 or IFNAR2 protein (1μg/ml) was coated on 96-well plate overnight at 4℃. Then 100μl diluted immunoconjugates in 1%BSA/PBST were supplemented and incubated with IFNAR1 or IFNAR2 for 1 hour. 100μl goat anti-human IgG Fc HRP was added for analysis by spectrophotometer at 450nm.
As shown in FIG. 5A and FIG. 5B, consistent with the Biacore results, L1IF M205 with S152C substitution in the IFNa2b component of the immunoconjugate exhibited comparable binding affinity with IFNAR1 but attenuated binding with IFNAR2 as compared with L1IF WT, and L1IF M205 DAR1 with S152C substitution and an additional chemical moiety attached to the substituted residue in the IFNa2b component of the immunoconjugate exhibited further attenuated binding to both IFNAR1 and IFNAR2 as compared to L1IF M205.
Example 5. Activation of INFα signaling by the immunoconjugates
IFNα2b signaling reporter assay and Daudi proliferation inhibition assay were performed to evaluate activation of INFα signaling by the immunoconjugate of the present application. Briefly, HEK-Blue IFN-α/β cells (at a density of 5.0 x 104 cells per well) were plated in a white 96-well plate. Then immunoconjugates including L1IF WT, L1IF M205, L1IF M205 DAR1 and L1IF M205 DAR2 were supplemented, respectively, and incubated with the cells at 37℃ for 6 hours, followed by measurement of luminescence.
As shown in FIG. 6A, L1IF M205 with S152C substitution in the IFNa2b component of the immunoconjugate exhibited reduced activation of Type I interferon signaling as compared with L1IF WT, and L1IF M205 DAR1 and L1IF M205 DAR2 with S152C substitution and an additional chemical moiety attached to the substituted residue in the IFNa2b component of the immunoconjugate exhibited further reduced activation of Type I interferon signaling as compared to L1IF M205.
Daudi cells (at a density of 2.0 x 104 cells per well) were plated in a 96-well plate. Then immunoconjugates including L1IF WT, L1IF M205, L1IF M205 DAR1 and L1IF M205 DAR2 were supplemented, respectively, and incubated with the cells at 37℃ for 3 days. Then titer-glo detection buffer (Promega) was added and incubated for 3 mins, followed by measurement of luminescence via Envision.
As shown in FIG. 6B, L1IF M205 with S152C substitution in the IFNa2b component of the immunoconjugate exhibited significant inhibition on Daudi proliferation, L1IF M205 DAR1 and L1IF M205 DAR2 with S152C substitution and an additional chemical moiety attached to the substituted residue in the IFNa2b component of the immunoconjugate exhibited further inhibition on Daudi proliferation as compared to L1IF M205.
Example 7. In vitro efficacy of the immunoconjugate
In vitro tumor killing efficacy of the immunoconjugates of the present application was evaluated by using human colon rectal cancer cell line RKO cells as target cells and primary CD8 T cells as effector cells, as illustrated in FIG. 7A.
Briefly, primary CD8 T cells were isolated from human PBMC through Milteny kit and then co-cultured at a density of 5.0 x 104 cells per well with 1.0 x 104 RKO cells labeled with CellTrace in a 96-well plate. The immunoconjugates of the present application including L1IF WT, L1IF M205, L1IF M205 DAR1 and L1IF M205 DAR2 respectively were serially diluted and added to the plate and incubated with the cells for 3 days, followed by analysis of the counts of viable RKO cells through FACS.
As shown in FIG. 7B, similarly as L1IF WT, L1IF M205 exhibited dose dependent tumor killing activity. In contrast, L1IF M205 DAR1 and L1IF M205 DAR2 did not exhibit tumor killing activity, indicating attenuation of activation of Type I interferon signaling due to the modification by the chemical moiety of the present application. After cleavage by Legumain, dose dependent tumor killing activity of L1IF M205 DAR1was resumed, as shown in L1IF M205 active group.
Example 8. In vivo efficacy of the immunoconjugates
In vivo anti-tumor activity of the immunoconjugates of the present application was evaluated in CB-17 SCID RKO mouse model.
Briefly, RKO cells (PD-L1 positive but anti-PD-L1 treatment resistant colorectal cancer
cell line) were s. c inoculated into human PBMC reconstruction CB-17 mice (purchased from Vital River Laboratory) . When the tumor volume reached to about 40 mm3, the mice were randomly divided into 6 groups, and the immunoconjugates including L1IF WT, L1IF M205, and L1IF M205 DAR1 were administrated to the mice based on the regimen shown in FIG. 8.
As shown in FIG. 8, in the model, L1IF WT, L1IF M205, L1IF M205 DAR1 all exhibited stronger TGI anti-tumor efficacy as compared to the Tecentriq group, and L1IF WT demonstrated superior antitumor efficacy over Tecentriq plus peg-IFNα2b group (TGI 47.81 %vs 18.10%) . At the dose of 3mg/kg, L1IF M205 DAR1 exhibited even superior anti-tumor efficacy as compared to L1IF WT (TGI 66.73%vs 47.81%) , suggesting resumed and improved anti-tumor activity of L1IF M205 DAR1.
Example 9. Toxicology of the immunoconjugates
In vivo toxicity of the immunoconjugates of the present application was further evaluated. As shown in FIG. 9, after administration, L1IF M205 DAR 1 exhibited more stable lymphocytes and platelet counts, indicating reduced hematologic toxicity induced by L1IF M205 DAR1.
Example 10. Bifunctional polypeptides with new anti-PD-L1 antibody
In this example, a new anti-PD-L1 nanobody (112_08) was generated, and used to prepare immunoconjugates similar to those described above. The 112_08 nanobody has an amino acid sequence of SEQ ID NO: 49.
Two formats of bifunctional polypeptides were made, as illustrated in FIG. 10 and their sequences are shown in Table 6 below. One of them (112_08-IFM) was symmetrical, containing two copies of the IFNα2b S152C variant at the C-terminus of the Fc fragment. The other one (112_08-IFM-knob) contained a single IFNα2b S152C variant, and the knob-in-hole substitutions to reduce mispairing. Immunoconjugates based on these two bifunctional polypeptides were prepared, each containing a single chemical moiety 112_08-IFM DAR1 and 112_08-IFM-knob DAR1.
Table 6. Amino acid sequences of immunoconjugates
The activities of these bi-functional polypeptides and the corresponding immunoconjugates were tested with ELISA, IFNa reporter assay and Daudi cell binding assay, as described above. As shown in FIG. 11, the bi-functional polypeptides exhibited high activity while the immunoconjugates had much attenuated infinity towards IFNAR2.
112_08-IFM-knob was also subjected to testing for binding and inhibiting PD-L1. Encouragingly, it exhibited more potent binding and greater inhibitory activity than Tecentriq (FIG. 12) .
Moreover, the in vivo anti-tumor activities of these bi-functional polypeptides and
immunoconjugates were tested in the CB-17 SCID RKO model (see methodology in Example 8) . As shown in FIG. 13 and Table 5, at least the asymmetric112_08-IFM-knob and both immunoconjugates outperformed the combination of Tecentriq and PEG-IFNα.
Table 5. In vivo antitumor efficacy
This example, therefore, has demonstrated the excellent performance of the new anti-PD-L1 nanobody in the context of bi-functional polypeptides and immunoconjugates.
***
The present disclosure has been described in terms of particular embodiments found or proposed by the present inventor to comprise preferred modes for the practice of the disclosure. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the disclosure. For example, due to codon redundancy, changes can be made in the underlying DNA sequence without affecting the protein sequence. Moreover, due to biological functional equivalency considerations, changes can be made in protein structure without affecting the biological action in kind or amount. All such modifications are intended to be included within the scope of the appended claims.
SEQUENCE LISTING
Claims (60)
- A polypeptide comprising an IFNα2b or a functional fragment thereof, wherein the IFNα2b or the functional fragment thereof is modified, as compared to the wild-type IFNα2b protein, to attenuate binding affinity to interferon α/β receptor, wherein (a) the polypeptide is a multi-functional polypeptide or (b) the polypeptide is conjugated to a chemical moiety.
- The polypeptide of claim 1, wherein the interferon α/β receptor is selected from IFNAR1, IFNAR2, and the combination thereof.
- The polypeptide of claim 1 or 2, wherein the binding affinity of the IFNα2b or the functional fragment thereof with the interferon α/β receptor is attenuated by at least 10 folds, 102 folds, 103 folds, 104 folds or 105 folds.
- A polypeptide comprising an IFNα2b or a functional fragment thereof, wherein the IFNα2b or the functional fragment thereof is modified, as compared to the wild-type IFNα2b protein, to attenuate activity to induce Type I interferon signaling.
- The polypeptide of claim 4, wherein the activity to induce Type I interferon signaling is attenuated by at least 10 folds, 102 folds, 103 folds, 104 folds or 105 folds.
- The polypeptide of any one of claims 1-5, wherein the IFNα2b or the functional fragment thereof is modified by an amino acid substitution at one or more residues corresponding to the residues selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1.
- The polypeptide of any one of claims 1-6, wherein the modification comprises an amino acid substitution at the residue corresponding to S152 of SEQ ID NO: 1.
- The polypeptide of any one of claims 1-7, wherein the modification comprises an amino acid substitution with cysteine at the residue corresponding to S152 of SEQ ID NO: 1.
- The polypeptide of any one of claims 1-8, wherein the IFNα2b comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%or 100%sequence identity to the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
- The polypeptide of any one of claims 1-9, wherein the IFNα2b or the functional fragment thereof is conjugated to a chemical moiety.
- The polypeptide of claim 10, wherein the chemical moiety comprises a structure of formula (I) :
R1-R2-R3-R4 (I) ,wherein,R1 iswhich is optionally further substituted with 1, 2 or 3 R*group (s) ;L1 is selected from CH or N;R1a is absent, or is selected from the group consisting of - (CH2) 0-3-C (O) -, - (CH2) 0-3-OC (O) -, and - (CH2) 0-3-NHC (O) -;each R1b is independently absent, or is independently selected from the group consisting of -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-, -NH-C1-6 alkyl-, -O-C1-6 alkyl-, -C (O) -C1-6 alkyl-, -OC (O) -C1-6 alkyl-, -C (O) O-C1-6 alkyl-and -C (O) NH-C1-6 alkyl-;each R1c is independently selected from the group consisting of H, C1-6 alkyl, and C1-6 haloalkyl;m is an integer in a range of 1 to 30000;R*is selected from H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl, or C2-6 alkynyl;R2 is a linker which is cleavable under tumor environment;R3 isX is selected from -NH-or -O-;Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, -C (O) -C (O) -or -NHC (O) -;each Rx and Ry is independently selected from H, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl;n is 0, 1, 2, 3, 4, or 5;R4 isRa and Rb are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxyl;R4a is absent, or is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-, (C1-6 alkylene-O) p- (CH2) 1-12, - (CH2) 1-12-C3-8 cycloalkylene-, - (CH2) 1-12-C3-8 cycloalkylene- (CH2) 1-12, - (CH2) 1-12-C6-10 arylene-, and - (CH2) 1-12-C6-10 arylene- (CH2) 1-12;R4a is optionally further substituted with 1, 2, 3, 4 or 5 R#group (s) ;R4b is selected from the group consisting of -NH-, -O-, -C (O) -, -C (O) O-, -OC (O) -, -C (O) -C (O) -, -C (O) NH-or -NHC (O) -;R#is selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-6 alkenyl or C2-6 alkynyl;p is 1, 2, 3, 4 or 5;wherein R3 links to R2 via the X of R3, and links to R4 via the Y of R3. - The polypeptide of claim 11, wherein,R1 iswhich is optionally further substituted with 1, 2 or 3 R*group (s) ;L1 is selected from CH or N;R1a is absent, or is selected from the group consisting of -C (O) -, -OC (O) -, and -NHC (O) -;each R1b is independently absent, or is independently selected from the group consisting of -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-, -NH-C1-4 alkyl-, -O-C1-4 alkyl-, -C (O) -C1-4 alkyl-, -OC (O) -C1-4 alkyl-, -C (O) O-C1-4 alkyl-and -C (O) NH-C1-4 alkyl-;each R1c is independently selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl;each m is independently an integer in a range of 1 to 5000;R*is selected from H, halogen, C1-6 alkyl or C1-6 haloalkyl;alternatively, R1 iswhich is optionally further substituted with 1, 2 or 3 R*group (s) ;R1a is absent, or is -C (O) -;R1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl;m is an integer in a range of 1 to 3000;R*is selected from H, halogen or C1-4 alkyl;still alternatively, R1 isR1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500; yet alternatively, R1 is a linear polyethylene glycol having a molecular weight of about 20000.
- The polypeptide of claim 11 or 12, wherein R2 is selected from the group consisting of matrix metalloprotease (MMP) cleavable linker, a disintegrin and metalloprotease domain-containing (ADAM) metalloprotease cleavable linker, a prostate specific antigen (PSA) protease cleavable linker, a urokinase-type plasminogen activator (uPA) protease cleavable linker, a membrane type serine protease 1 (MT-SP1) protease cleavable linker, a matriptase protease cleavable linker (ST14) and a legumain protease cleavable linker.
- The polypeptide of claim 13, wherein R2 is a matrix metalloprotease (MMP) cleavable linker and comprises an amino acid sequence of anyone selected from SEQ ID NOs: 21-35.
- The polypeptide of claim 13, wherein R2 is a prostate specific antigen (PSA) protease cleavable linker and comprises an amino acid sequence of anyone selected from SEQ ID NOs: 14-16.
- The polypeptide of claim 13, wherein R2 is urokinase-type plasminogen activator (uPA) protease cleavable linker and comprises an amino acid sequence of anyone selected from SEQ ID NOs: 11-13.
- The polypeptide of claim 13, wherein R2 is a legumain protease cleavable linker and comprises an amino acid sequence of anyone selected from SEQ ID NOs: 18-19 or AAN or Cbz-AAN-AMC.
- The method of any one of claims 11-13 and 17, wherein the chemical moiety comprises a structure of formula (II) :
wherein R1, R3 and R4 are as defined in any one of claims 11-13 and 17. - The polypeptide of any one of claims 11-18, whereinR3 iswherein,X is selected from -NH-or -O-;Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -;each Rx and Ry is independently selected from H, halogen, C1-4 alkyl or C1-4 haloalkyl;n is 0, 1, 2 or 3;alternatively,R3 isX is selected from NH or O;Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -.
- The method of any one of claims 11-19, wherein the chemical moiety comprises a structure of formula (III) :
wherein,X is selected from NH or O;Y is selected from -NH-, -O-, -C (O) -, -OC (O) -, or -NHC (O) -;wherein R1, R2 and R4 are as defined in any one of claims 11-19. - The polypeptide of any one of claims 11-20, wherein the chemical moiety comprises a structure of formula (IV) :
wherein R1 and R4 are as defined in any one of claims 11-20. - The polypeptide of any one of claims 11-21, wherein:R4 isRa and Rb are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxyl;R4a is absent, or is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-, (C1-6 alkylene-O) p- (CH2) 1-12, - (CH2) 1-12-C3-8 cycloalkylene- and - (CH2) 1-12-C3-8 cycloalkylene- (CH2) 1-12;R4a is optionally further substituted with 1, 2, 3 or 4 R#group (s) ;R4b is -NH-, -O-, -C (O) -, -OC (O) -, -C (O) O-, -C (O) NH-or -NHC (O) -;R#is selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl;p is 1, 2, 3 or 4;alternatively,Ra and Rb are each independently selected from the group consisting of H and C1-4 alkyl;R4a is selected from the group consisting of - (CH2) 1-12-, - (CH2) 1-12-O-, -O- (CH2) 1-12-, -O- (CH2) 1-12-O-, - (CH2) 1-12-O- (CH2) 1-12-and (C1-4 alkylene-O) p- (CH2) 1-12;R4a is optionally further substituted with 1, 2 or 3 R#group (s) ;R4b is -NH-, -O-or -C (O) -;R#is selected from the group consisting of H, halogen, C1-6 alkyl and C1-6 haloalkyl;p is 1, 2 or 3;still alternatively,Ra and Rb are H;R4a is - (CH2) 2-12-;R4b is -NH-;R4a is optionally further substituted with 1 or 2 R#group (s) ;R#is selected from the group consisting of H, halogen and C1-4 alkyl.
- The polypeptide of any one of claims 11-22, wherein the chemical moiety comprises a structure of formula (V) :
wherein R1, R2 and R3 are as defined in any one of claims 11-22. - The polypeptide of any one of claims 11-23, wherein the chemical moiety comprises a structure of formula (VI) :
wherein, the PEGm isR1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500. - The polypeptide of claim 24, wherein the PEGm is a linear polyethylene glycol having a molecular weight of about 20000.
- The polypeptide of any one of claims 11-25, wherein the IFNα2b or the functional fragment thereof is modified by the chemical moiety at a residue corresponding to the residue selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1.
- The polypeptide of claim 26, wherein the IFNα2b or the functional fragment thereof comprises an amino acid substitution with a cysteine at a position corresponding to the position selected from the group consisting of R12, L15, M16, R22, L26, F27, L30, R33, R33, H34, D35, A145, M148, R149, S152, L153, and N156 of SEQ ID NO: 1, and the chemical moiety is linked to the IFNα2b or the functional fragment via the cysteine.
- The polypeptide of claim 27, wherein the R4 of the chemical moiety is linked to the S atom of the cysteine residue via a maleimide, an acetylene, a vinyl, a mono-substituted butenedioic acid, or a disubstituted maleimide.
- The polypeptide of any one of claims 1-28, wherein the IFNα2b or the functional fragment thereof is conjugated to a biomolecule specifically binding to a target.
- The polypeptide of claim 29, wherein the IFNα2b or the functional fragment thereof is conjugated to the biomolecule directly.
- The polypeptide of claim 29, wherein the IFNα2b or the functional fragment thereof is conjugated to the biomolecule via a linker.
- The polypeptide of any one of claims 29-31, wherein the biomolecule comprises an antibody or an antigen binding fragment thereof.
- The polypeptide of claim 32, wherein the antibody or the antigen binding fragment thereof is selected from the group consisting of a full-length antibody, a Fab, Fab’, a F (ab’) 2, a Fd, a Fd’, a Fv, a scFv, a ds-scFv, a sdAb and a nanobody.
- The polypeptide of any one of claims 28-33, wherein the target is PD-L1 or PD-1.
- The polypeptide of claim 34, wherein the biomolecule comprises a sdAb comprising a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 49, and the CDR1, CDR2 and CDR3 are according to Kabat numbering scheme.
- The polypeptide of claim 34, wherein the biomolecule comprises a sdAb comprising:(i) aCDR1 comprising the amino acid sequence of SEQ ID NO: 50,(ii) aCDR2 comprising the amino acid sequence of SEQ ID NO: 51, and(iii) aCDR3 comprising the amino acid sequence of SEQ ID NO: 52.
- The polypeptide of claims 35 or 36, wherein the biomolecule comprises a sdAb, and the sdAb comprises a sequence having at least 80%identity with SEQ ID NO: 49.
- The polypeptide of any one of claims 35 to 37, wherein the biomolecule further comprises a Fc region.
- A multi-functional polypeptide, comprising an IFNα2b or a functional fragment thereof of any one of claims 1-28, and an antibody or antigen-binding fragment thereof.
- The multi-functional polypeptide of claim 39, which includes a single copy of the IFNα2b or functional fragment thereof.
- The multi-functional polypeptide of claim 39 or 40, which comprises an Fc fragment.
- The multi-functional polypeptide of claim 41, wherein the IFNα2b or a functional fragment thereof is disposed on the C-terminal side of the Fc fragment.
- The multi-functional polypeptide of any one of claims 39 to 42, wherein the antibody or antigen-binding fragment thereof is disposed on the N-terminal side of the Fc fragment.
- The multi-functional polypeptide of any one of claims 41 to 43, wherein the Fc fragment comprises knob-in-hole substitutions as compared to the corresponding wild-type Fc fragment.
- The multi-functional polypeptide of any one of claims 41 to 44, wherein the antibody or antigen-binding fragment thereof has specificity to a tumor associated antigen or immune checkpoint protein.
- The multi-functional polypeptide of claim 45, wherein the tumor associated antigen is selected from the group consisting of EGFR, Her2, EpCAM, CD20, CD30, CD33, CD47, CD52, CD133, CD73, CEA, gpA33, Mucins, TAG-72, CIX, PSMA, folate-binding protein, GD2, GD3, GM2, VEGF, VEGFR, Integrin, aVb3, a5b1, ERBB2, ERBB3, MET, IGF1R, EPHA3, TRAILR1, TRAILR2, RANKL, FAP, Tenascin, and Claudin 18.2.
- The multi-functional polypeptide of claim 45, wherein the immune checkpoint protein is selected from the group consisting of PD-1, PD-L1, CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX-40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM, BTLA, KIR, and CD47.
- The multi-functional polypeptide of claim 47, wherein antibody or antigen-binding fragment thereof is an anti-PD-L1 or anti-PD-1 single domain antibody (sdAb) .
- The multi-functional polypeptide of claim 48, wherein the anti-PD-L1 sdAb comprises a CDR1, a CDR2 and a CDR3 of SEQ ID NO: 49, and the CDR1, CDR2 and CDR3 are according to Kabat numbering scheme.
- The multi-functional polypeptide of claim of 48, wherein the anti-PD-L1 sdAb comprises:(i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 50,(ii) a CDR2 comprising the amino acid sequence of SEQ ID NO: 51, and(iii) a CDR3 comprising the amino acid sequence of SEQ ID NO: 52.
- The multi-functional polypeptide of claim of 49 or 50, wherein the anti-PD-L1 sdAb comprises a sequence having at least 80%identity to SEQ ID NO: 49.
- The multi-functional polypeptide of any one of claims 39-51, wherein the IFNα2b comprises the amino acid sequence having at least 80%identity with SEQ ID NO: 1 or SEQ ID NO: 2.
- An immunoconjugate comprising a multi-functional polypeptide of any one of claims 39-52 conjugated with a chemical moiety.
- The immunoconjugate of claim 53, wherein the chemical moiety comprises a structure of formula (VI) :
wherein, the PEGm isR1c is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl, m is an integer in range of 1 to 1000, 100 to 500 or 400 to 500;alternatively, the PEGm is a linear polyethylene glycol having a molecular weight of about 20000. - A polynucleotide encoding the polypeptide of any one of claims 1-38, or the multi-functional polypeptide of any one of claims 39-52.
- A vector comprising the polynucleotide of claim 55.
- A host cell comprising the vector of claim 56.
- A pharmaceutical composition comprising the polypeptide of claims 1-38, multi-functional polypeptide of any one of claims 39-52, the immunoconjugate of claim 53 or 54, or the polynucleotide of claim 55.
- A method for treating a disorder in a subject in need thereof, comprising administrating an effective amount of the polypeptide of claims 1-38, multi-functional polypeptide of any one of claims 39-52, the immunoconjugate of claim 53 or 54, or the polynucleotide of claim 55 to the subject.
- The method of claim 59, wherein the disorder is cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022132200 | 2022-11-16 | ||
CNPCT/CN2022/132200 | 2022-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024104412A1 true WO2024104412A1 (en) | 2024-05-23 |
Family
ID=91083866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/131937 WO2024104412A1 (en) | 2022-11-16 | 2023-11-16 | Attenuated interferon proteins and fragments and multifunctional polypeptides and conjugates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024104412A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101514229A (en) * | 2009-04-03 | 2009-08-26 | 海南四环心脑血管药物研究院有限公司 | Human interferon alpha derivative and polyethylene glycol modified substance thereof |
CN104203982A (en) * | 2011-10-28 | 2014-12-10 | 特瓦制药澳大利亚私人有限公司 | Polypeptide constructs and uses thereof |
WO2018144999A1 (en) * | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
CN108727504A (en) * | 2018-04-16 | 2018-11-02 | 中国科学院生物物理研究所 | The fusion protein and its application of a kind of IFN and anti-PD-L1 antibody |
WO2019091384A1 (en) * | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
-
2023
- 2023-11-16 WO PCT/CN2023/131937 patent/WO2024104412A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101514229A (en) * | 2009-04-03 | 2009-08-26 | 海南四环心脑血管药物研究院有限公司 | Human interferon alpha derivative and polyethylene glycol modified substance thereof |
CN104203982A (en) * | 2011-10-28 | 2014-12-10 | 特瓦制药澳大利亚私人有限公司 | Polypeptide constructs and uses thereof |
WO2018144999A1 (en) * | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
WO2019091384A1 (en) * | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
CN108727504A (en) * | 2018-04-16 | 2018-11-02 | 中国科学院生物物理研究所 | The fusion protein and its application of a kind of IFN and anti-PD-L1 antibody |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102426765B1 (en) | Novel bispecific polypeptide for CD137 | |
TWI772586B (en) | Tri-chain antibody, preparation method and use thereof | |
CN112867734A (en) | PD-1 targeting heterodimeric fusion proteins comprising an IL-15/IL-15Ra Fc fusion protein and a PD-1 antigen binding domain and uses thereof | |
JP2020512814A (en) | Immunoconjugate | |
KR20180028548A (en) | SIRP-alpha domain or a variant thereof | |
CN113423734A (en) | PD-1 targeted IL-15/IL-15R alpha FC fusion protein and application thereof in combination therapy | |
CN113195523A (en) | IL-12 heterodimer Fc fusion proteins | |
JP2021528988A (en) | New bispecific agonist 4-1BB antigen-binding molecule | |
EP4017594A1 (en) | Novel il-21 prodrugs and methods of use thereof | |
CN113301919A (en) | Bispecific antibodies that activate immune cells | |
US20230272110A1 (en) | Antibodies that bind psma and gamma-delta t cell receptors | |
TW202219065A (en) | Immune activating Fc domain binding molecules | |
CN113811549A (en) | Non-targeted and targeted IL-10 FC fusion proteins | |
WO2019129054A1 (en) | Triabody, preparation method and use thereof | |
US20230331809A1 (en) | Fusion proteins comprising a ligand-receptor pair and a biologically functional protein | |
KR20210027254A (en) | Antibodies to TIM-3 and uses thereof | |
WO2022224997A1 (en) | Anti-cldn4/anti-cd137 bispecific antibody | |
JP2022553129A (en) | Antibodies against poliovirus receptor (PVR) and uses thereof | |
EP4194002A1 (en) | Tgf-? rii mutant and fusion protein thereof | |
TW202235104A (en) | Bi-functional molecules | |
CN116888153A (en) | Antibodies that bind to gamma-delta T cell receptors | |
WO2024104412A1 (en) | Attenuated interferon proteins and fragments and multifunctional polypeptides and conjugates | |
CA3191454A1 (en) | Fusion protein comprising il-12 and anti-fap antibody, and use thereof | |
CA3164646A1 (en) | Antibodies conjugated with fatty acid molecules and uses thereof | |
CN114867751A (en) | 4-1BB and OX40 binding proteins and related compositions and methods, anti-4-1 BB antibodies, anti-OX 40 antibodies |